Document:

Exhibit 10.10

 

CONTRIBUTION
AND EXCHANGE AGREEMENT

 

THIS
CONTRIBUTION AND EXCHANGE AGREEMENT (this “Agreement”) is entered into as of November 29, 2021 by and among GSP Nutrition,
Inc., a Delaware corporation (“GSP Nutrition”), the shareholders of GSP Nutrition, Inc. set forth on Schedule A
hereto (each, a “GSP Shareholder” and collectively, the “GSP Shareholders”), and Smart for
Life, Inc., a Delaware corporation (the “Company”).

 

RECITALS

 

WHEREAS,
each GSP Shareholder owns the number of shares of common stock, par value $0.001 per share (the “GSP Common Stock”),
of GSP Nutrition set forth opposite such GSP Shareholder’s name on Schedule A attached hereto (collectively, the “Outstanding
GSP Shares”); and

 

WHEREAS,
the Outstanding GSP Shares constitute all of the outstanding GSP Common Stock; and

 

WHEREAS,
the GSP Shareholders desire to contribute the Outstanding GSP Shares to the Company in exchange for the issuance by the Company to
the GSP Shareholders of an aggregate number of shares of common stock, par value $0.0001 per share (the “Company Common Stock”),
of the Company (the “Estimated Aggregate Company Share Issuance”) determined by dividing the Purchase Price (as defined
below) by $10.00 (the “Estimated PPS”), which Estimated Aggregate Company Share Issuance shall be subject to increase
as set forth herein if the IPO PPS (as defined herein) is less than the Estimated PPS (the contribution by the GSP Shareholders of the
Outstanding GSP Shares to the Company and the issuance by the Company to the GSP Shareholders of shares of Company Common Stock in exchange
thereof are referred to as, the “GSP Contribution Transactions”); and

 

WHEREAS,
the Estimated Aggregate Company Share Issuance shall be allocated among the GSP Shareholders as set forth on Schedule B hereto;
and

 

WHEREAS,
the parties desire to effect the GSP Contribution Transactions on the terms and conditions set forth herein.

 

NOW,
THEREFORE, in consideration of the foregoing premises, the mutual covenants herein contained, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.
Contribution and Exchange; Closing.

 

(a)
Contribution. On the Closing Date (as defined herein) and pursuant to the terms and conditions of this Agreement, each
GSP Shareholder shall contribute, transfer, assign and convey to the Company, free and clear of any lien, claim, charge, mortgage, pledge,
security interest, restriction or other encumbrance (collectively, “Encumbrances”), all right, title, and interest
in and to all of the Outstanding GSP Shares owned by such GSP Shareholder as set forth opposite such GSP Shareholder’s name on
Schedule A (each, a “GSP Shareholder Contribution” and collectively, the “GSP Shareholder Contributions”),
together with any and all rights, privileges and benefits appertaining thereto, reserving unto the GSP Shareholders no rights or interests
therein whatsoever.

 

     

     

    

 

(b)
Exchange. On the Closing Date and pursuant to
the terms and conditions of this Agreement, in exchange for the GSP Shareholder Contributions, the Company shall issue to each GSP Shareholder
the number of shares of Company Common Stock set forth opposite such GSP Shareholder’s name on Schedule B hereto (collectively,
the “Exchange”). In addition, if the IPO PPS is less than the Estimated PPS, the Estimated Aggregate Company Share
Issuance shall be increased to an amount determined by dividing the Purchase Price by the IPO PPS (the “Final Aggregate Company
Share Issuance”), and the Additional Company Shares (as defined below) shall be allocated among, and promptly issued to, the
GSP Shareholders based on their percentage ownership of the Outstanding GSP Shares immediately prior to the Closing.

 

(c)
Closing. The closing of the GSP Shareholder Contributions
and the Exchange (the “Closing”) shall take place remotely via the exchange of executed documents on the date
that is the second (2nd) business day following the satisfaction or waiver of the conditions set forth in Section 7
(other than any such condition required to be performed at the Closing, but subject to the satisfaction or waiver of such conditions
at the Closing), unless another date or method of Closing is agreed to in writing by the Company and the GSP Shareholders. The actual
date and time of the Closing are herein referred to as the “Closing Date.”

 

(d)
Satisfaction of Payables. The accounts payable
of GSP Nutrition as of the date hereof are set forth on Schedule 1(d), which schedule also identifies each Person to whom such accounts
payable are owed (each, a “Third-Party Vendor”). Those Third-Party Vendors that are willing to accept shares of the
Company’s Common Stock in full satisfaction of their accounts payable are listed on Schedule 1(d) under the heading “Satisfaction
in Company Common Stock” and those Third-Party Vendors that must be paid in cash are listed under the heading “Satisfaction
in Cash.” Schedule 1(d) shall be updated by GSP Nutrition at least two (2) days prior to the Closing. At the Closing, the Company
shall issue to each Third-Party Vendor the number of shares of Company Common Stock set forth opposite such Third-Party Vendor’s
name on Schedule 1(d) in satisfaction of the amounts owed to such Third-Party Vendor. The shares will be issued pursuant to a subscription
agreement in a form mutually agreed upon by GSP and the Company. The number of shares of Company Common Stock to be issued to the Third-Party
Vendors shall be subject to adjustment in a manner consistent with the adjustment in favor of the GSP Shareholders set forth in Section
1(b) above and as set forth in the applicable subscription agreement. At the Closing, the Company shall also pay, or cause GSP Nutrition
to pay, in cash to each Person listed on Schedule 1(d) under the heading “Satisfaction in Cash” the amounts set forth opposite
such Person’s name on Schedule 1(d). The total amount dollar value of accounts payable at the Closing shall not exceed $360,000.

 

2.
Defined Terms. For purposes of this Agreement,
the following terms shall have the respective meanings set forth below:

 

(a)
“Additional Company Shares” means
the amount by which the Final Aggregate Company Share Issuance exceeds the Estimated Aggregate Company Share Issuance.

 

    2

     

    

 

(b)
 “Affiliate” means, with respect to
the indicated Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with, the
indicated Person. For purposes of this definition, the terms “control”, “controlled by” and “under common
control with” means the possession directly or indirectly of the power to direct or cause the direction of the management and policies
of the indicated Person, whether through the ownership of voting securities, by trust, agreement, contract or otherwise.

 

(c)
“Applicable Law” means any applicable
federal, state, local, municipal, foreign or other law, statute, constitution, principle of common law, resolution, ordinance, code,
edict, decree, rule, regulation, judgment, ruling, order or other requirement issued, enacted, adopted, promulgated, implemented, rendered
or otherwise put into effect by or under the authority of any Governmental Entity.

 

(d)
“Governmental Entity” means any (i)
nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (ii) federal, state,
local, municipal, foreign or other government or (iii) governmental or quasi-governmental authority of any nature including any governmental
division, department, agency, taxing authority, commission, instrumentality, official, organization, unit or body and any court or other
tribunal.

 

(e)
“GSP Fundamental Representations”
means the representations and warranties made pursuant to Sections 3(a), 3(d), 3(e), 4(a), 4(c), 4(f) and 4(m).

 

(f)  
“GSP Material Adverse Effect” means
any material adverse effect on the assets, properties, condition (financial or otherwise), operations of GSP Nutrition, provided, however,
that a Material Adverse Effect shall not include: (i) changes in the national or world economy or financial markets as a whole or changes
in general economic conditions that affect the industries in which GSP Nutrition conducts its business, so long as such changes or conditions
do not adversely affect GSP Nutrition in a materially disproportionate manner relative to other similarly situated participants in the
industries or markets in which they operate; (ii) any change in applicable law or U.S. Generally Accepted Accounting Principles or interpretation
thereof after the date hereof, so long as such changes do not adversely affect GSP Nutrition in a materially disproportionate manner
relative to other similarly situated participants in the industries or markets in which they operate; (iii) the transactions contemplated
by this Agreement becoming public; or (iv) compliance with the terms of, and taking any action required by, this Agreement, or the taking
or not taking any actions at the request of, or with the consent of, the Company.

 

(g)
“Inventory” means all inventories
of raw materials, supplies, work-in-process, finished goods, and other materials used in or held for use in the business GSP Nutrition.

 

(h) “IPO
PPS” means the effective price per share of Company Common Stock as set forth in the final prospectus related to the
Company’s initial underwritten public offering of the Company Common Stock under the Securities Act of 1933, as amended (the
“Securities Act”). For the avoidance of doubt, the current proposed structure of the securities being sold in the
Company’s initial public offering is the sale of units consisting of one share, one warrant with an exercise price equal to
50% of the unit price and a second warrant with an exercise price equal to 100% of the unit price, but the second warrant
automatically becomes exercisable on a cashless basis without the payment of any consideration on the tenth day following the IPO
Date. Assuming an a initial public offering price per Unit of $10.00, the IPO PPS would be $5.00.

 

    3

     

    

 

(i)
“Percentage Interest” means, with
respect to a GSP Shareholder, a fraction, the numerator of which is the shares of Company Common Stock received by such GSP Shareholder
pursuant to Section 1(b) of this Agreement and the denominator of which is the aggregate number of shares of Company Common Stock issued
to all GSP Shareholders pursuant to Section 1(b) of this Agreement.

 

(j)
“Person” means any natural person,
corporation, partnership, limited liability company, limited company, company, trust, association, unincorporated organization, Governmental
Entity, or other legal entity.

 

(k)
“Purchase Price” means Four Hundred
Twenty Five Dollars ($425,000) minus, to the extent not paid by the GSP Nutrition before the Closing, the amount of all fees, costs and
expenses (including legal, accounting, investment banking, broker's, finder's and other professional or advisory fees and expenses) of
GSP Nutrition incurred by or on behalf of, or to be paid by, GSP Nutrition in connection with the negotiation and execution of this Agreement
and the other transaction documents and the consummation of the transactions contemplated by this Agreement (excluding any amounts due
and payable to any Person as set forth on Schedule 1(d) and the fees payable pursuant to Section 6(c) of this Agreement, which amounts
and fees shall not reduce the Purchase Price).

 

(l)
“Representatives” means, with respect
to any Person, the respective directors, officers, employees, counsel, accountants and other representatives of such Person.

 

(m)
“Specific GSP Shareholder” means
Stuart Benson, SIGroup Ventures, LLC, NutraGlobal, LLC, HCFP Capital Partners, LLC, HCFP Direct Investments and GSP Sports Brands, Inc.

 

(n)
“Taxes” means all federal, state,
local and foreign income, profits, franchise, gross receipts, environmental, customs duty, capital stock, severance, stamp, payroll,
sales, transfer, employment, unemployment, disability, use, property, withholding, excise, production, value added, occupancy and other
taxes, duties or assessments of any nature whatsoever, in each case, imposed by any Taxing Authority.

 

(o)
“Taxing Authority” means any governmental
entity having or purporting to exercise jurisdiction with respect to any Tax.

 

(p)
“Tax Returns” means any return, declaration,
report, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto, and including
any amendment thereof, filed or required to be filed with any Taxing Authority.

 

    4

     

    

 

(q) “Transaction
Proposal” means any written bona fide proposal made by a third party relating to (i) any direct or indirect acquisition or
purchase of all or substantially all of the assets of GSP Nutrition, (ii) any direct or indirect acquisition or purchase of a
majority of the combined voting power of the Outstanding GSP Shares, or (iii) any merger, consolidation, business combination,
recapitalization, liquidation, dissolution or similar transaction involving GSP Nutrition in which the other party thereto or its
stockholders will own 51% or more of the combined voting power of the parent entity resulting from any such transaction.

 

3.
Representations and Warranties of the GSP Shareholders.
Each GSP Shareholder hereby, severally and not jointly, represents and warrants to the Company as of the date hereof and as of the Closing
Date as follows:

 

(a)
Organization; Authority; Binding Agreement. 
With respect to each GSP Shareholder that is an entity, (i) such GSP Shareholder is a corporation, limited liability company or limited
partnership (as applicable), duly organized and validly existing under the laws of the state of its organization and (ii) the execution,
delivery and performance by such GSP Shareholder of this Agreement and any other document being delivered by such GSP Shareholder pursuant
to this Agreement have been duly authorized by all necessary corporate, limited liability company or limited partnership (as applicable)
action.  With respect to any GSP Shareholder that is an individual, such GSP Shareholder has full power and authority to enter into
this Agreement and any other document being delivered by such GSP Shareholder pursuant to this Agreement and to carry out his or her
obligations hereunder and to consummate the transactions contemplated hereby.  This Agreement is a valid and binding agreement of
such GSP Shareholder, enforceable against such GSP Shareholder in accordance with its terms, except as may be limited by bankruptcy,
insolvency, fraudulent conveyance, reorganization or similar laws affecting creditors’ rights generally or by general equitable
principles and except insofar as the enforceability of any provision of such agreement would be restricted or void by reason of public
policy.

 

(b)
Non-contravention.  The execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby will not (i) violate any agreement or contract to which
such GSP Shareholder is a party or by which such GSP Shareholder is bound, or any Applicable Law of any Governmental Entity having jurisdiction
over such GSP Shareholder or any order, judgment or decree applicable to such GSP Shareholder or (ii) result in the creation or imposition
of any Encumbrance on any of the Outstanding GSP Shares owned by such GSP Shareholder.

 

(c)
No Consents.  No notice to, filing with,
or authorization, registration, consent or approval of any Governmental Entity or other Person is necessary for the execution, delivery
or performance by such GSP Shareholder of this Agreement or the consummation of the transactions contemplated hereby.  The sale
of the Outstanding GSP Shares being contributed, transferred and assigned by such GSP Shareholder to the Company will not trigger any
right of first refusal or co-sale rights.

 

    5

     

    

 

(d) Ownership
of Outstanding GSP Shares.  Such GSP Shareholder owns the Outstanding GSP Shares set forth opposite such GSP
Shareholder’s name on Schedule A hereto, free and clear of all Encumbrances.  The Outstanding GSP Shares set forth
opposite such GSP Shareholder’s name on Schedule A hereto are the only shares of capital stock of GSP owned, directly
or indirectly, by such GSP Shareholder, and such GSP Shareholder has no convertible notes or other convertible securities, options,
rights or warrants to purchase additional shares of capital stock of GSP Nutrition.  After giving effect to the GSP Shareholder
Contribution of such GSP Shareholder, such GSP Shareholder shall have no ownership interest in GSP Nutrition and GSP Nutrition shall
not be indebted to such GSP Shareholder for any amounts.  Such GSP Shareholder has the absolute and unrestricted right, power
and capacity to contribute, transfer and assign such GSP Shareholder’s Outstanding GSP Shares to the Company, free and clear
of any Encumbrances.  The Outstanding GSP Shares being contributed, transferred and assigned by the GSP Shareholders, as set
forth on Schedule A hereto, represent one hundred percent (100%) of the outstanding capital stock of GSP Nutrition, and,
subject to Section 7(a)(vi), as of the Closing Date no Person has any rights, options or warrants to purchase shares of
capital stock or other equity interests of GPS Nutrition (whether from GSP Nutrition or from any third party).

 

(e)
Brokers’ and Finders’ Fees. 
Such GSP Shareholder has not incurred, nor will such GSP Shareholder incur, directly or indirectly, any liability for brokerage or finders’
fees or agents’ commissions or any similar charges in connection with this Agreement or the transactions contemplated hereby.

 

(f)  
Legal Proceedings.  There are no claims,
actions, causes of action, demands, lawsuits, arbitrations, inquiries, audits, notices of violation, proceedings, litigation, citations,
summons, subpoenas, or investigations of any nature, whether at law or in equity pending or threatened against or by such GSP Shareholder.

 

(g)
Affiliate Agreements.  GSP Nutrition is
not a party to, or bound by, any written or oral agreement or arrangement with such GSP Shareholder, any family member thereof or any
Person Affiliated with such GSP Shareholder or family member.  No GSP Shareholder or any family member or Affiliate thereof (i)
owns any property or right, tangible or intangible, that is used by GSP Nutrition or any of its subsidiaries in the operation or conduct
of its business or (ii) has any claim or cause of action against GSP Nutrition.

 

(h)
Investment Representations. With respect to the
Company Common Stock to be issued to such GSP Shareholder in connection with the Exchange:

 

(i)
Such GSP Shareholder acknowledges that such GSP Shareholder
has received all the information that such GSP Shareholder considers necessary or appropriate for deciding whether to acquire the Company
Common Stock. Such GSP Shareholder further represents that such GSP Shareholder has had an opportunity to ask questions and receive answers
from the Company regarding the Company and the Company Common Stock.

 

(ii)   
Such GSP Shareholder acknowledges that such GSP Shareholder
can bear the economic risk of his, her or its investment, and has such knowledge and experience in financial or business matters that
makes such GSP Shareholder capable of evaluating the merits and risks of the investment in the Company Common Stock.

 

(iii)    
Such GSP Shareholder is an “accredited investor”
within the meaning of Rule 501 of Regulation D, as presently in effect, as promulgated by the Securities and Exchange Commission (the
“SEC”) under the Securities Act.

 

    6

     

    

 

(iv)
 Such GSP Shareholder acknowledges that the Company Common
Stock are characterized as “restricted securities” under the federal securities laws insofar as they are being acquired from
the Company in a transaction not involving a public offering and that under such laws and applicable regulations the Company Common Stock
may not be resold without registration under the Securities Act except in certain limited circumstances. Therefore, such GSP Shareholder
represents that he, she or it is familiar with Rule 144, as presently in effect, as promulgated by the SEC under the Securities Act,
and understands the resale limitations imposed thereby and by the Securities Act.

 

(v)
Such GSP Shareholder recognizes that an investment in
the Company Common Stock involves a high degree of risk, including, but not limited to, the risk of economic losses from operations of
the Company.

 

(vi)
Such GSP Shareholder is in a financial position to hold
the Company Common Stock for an indefinite period of time and is able to bear the economic risk and withstand a complete loss of such
GSP Shareholder’s investment in the Company Common Stock.

 

(vii)   
Such GSP Shareholder is a bona fide resident of, is
domiciled in and received the offer and made the decision to be issued the Company Common Stock in the state identified in the address
of such GSP Shareholder on the signature pages hereto.

 

4.
Representations and Warranties Concerning GSP Nutrition.
Each Specific GSP Shareholder (but not any non-Specific GSP Shareholder) hereby, severally and not jointly, represents and warrants to
the Company as of the date hereof and as of the Closing Date as follows:

 

(a)
Organization; Standing and Power; Authority and Enforceability.
Organization; Authority; Binding Agreement. GSP Nutrition is a corporation duly organized and validly existing under the laws
of the State of Delaware. The execution, delivery and performance by GSP Nutrition of this Agreement and any other document being delivered
by the GSP Nutrition pursuant to this Agreement have been duly authorized by all necessary corporate action. This Agreement is a valid
and binding agreement of GSP Nutrition, enforceable against GSP Nutrition in accordance with its terms, except as may be limited by bankruptcy,
insolvency, fraudulent conveyance, reorganization or similar laws affecting creditors’ rights generally or by general equitable
principles and except insofar as the enforceability of any provision of such agreement would be restricted or void by reason of public
policy.

 

(b)
No Subsidiaries. GSP Nutrition does not have
any subsidiaries, nor does it control, directly or indirectly, or have any direct or indirect equity participation in any corporation,
partnership, trust, or other business association.

 

(c)
Capitalization.

 

(i)
Schedule 4(c) sets forth the authorized, issued and
outstanding securities of GSP Nutrition and identifies each of the owners of such securities.

 

    7

     

    

 

(ii)   
 GSP Nutrition has no plans or agreements pursuant to
which it has granted or committed to grant any option or right to acquire capital stock or any other award payable in or based upon the
capital stock of GSP Nutrition. There are no outstanding options, warrants or other securities or subscription, preemptive or other rights
convertible into or exchangeable or exercisable for any capital stock or other equity or voting interests of GSP Nutrition and there
are no “phantom interest” rights, interest appreciation rights or other similar rights with respect to GSP Nutrition. There
are no contracts of any kind to which GSP Nutrition is a party or by which GSP Nutrition is bound, obligating GSP Nutrition to issue,
deliver, grant or sell, or cause to be issued, delivered, granted or sold, additional capital stock or other equity or voting interests
in, or options, warrants or other securities or subscription, preemptive or other rights convertible into, or exchangeable or exercisable
for, capital stock, or other equity or voting interests in, GSP Nutrition, or any “phantom interests” right, interest appreciation
right or other similar right with respect to GSP Nutrition, or obligating GSP Nutrition to enter into any such contract.

 

(iii)    
There are no securities or other instruments or obligations
of GSP Nutrition, the value of which is in any way based upon or derived from any equity or voting interests of GSP Nutrition or having
the right to vote (or convertible into, or exchangeable or exercisable for, securities having the right to vote) on any matters on which
any of GSP Nutrition’ members may vote.

 

(iv)
There are no contracts, contingent or otherwise, obligating
GSP Nutrition to repurchase, redeem or otherwise acquire any capital stock of, or other equity or voting interests in, GSP Nutrition.
There are no voting trusts, registration rights agreements or stockholder or member agreements to which GSP Nutrition is a party with
respect to the voting of capital stock in GSP Nutrition or with respect to the granting of registration rights for any of the capital
stock in GSP Nutrition. There are no rights plans affecting GSP Nutrition.

 

(v)
GSP Nutrition has no outstanding indebtedness for borrowed
money.

 

(d)
Non-contravention. The execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby will not (i) violate any agreement or contract to which
GSP Nutrition is a party or by which GSP Nutrition is bound (or the organizational documents of GSP Nutrition), or any applicable law
of any governmental entity having jurisdiction over GSP Nutrition or any order, judgment or decree applicable to GSP Nutrition or (ii)
result in the creation or imposition of any encumbrance on any assets of the GSP Nutrition.

 

(e) Financial
Statements. Schedule 4(e) contains true and complete copies of (i) the unaudited combined balance sheet of GSP Nutrition as of
December 31, 2020 and December 31, 2019 and the related unaudited combined statements of income, stockholders’ equity and cash
flows for the two years ended December 31, 2020 and December 31, 2019 (the “Annual Financial Statements”) and
(ii) the unaudited combined balance sheet of GSP Nutrition and their Subsidiaries as of September 30, 2021 and the related
statements of income, stockholders’ equity and cash flows for the nine-month period ended September 30, 2021 (the
“Interim Financial Statements” and, together with the Annual Financial Statements, the “Financial
Statements”). Except as set forth in Schedule 4.5, the Financial Statements fairly present, in all material respects, the
financial condition and results of operations of GSP Nutrition as of the indicated dates and for the indicated periods (subject to
normal year-end adjustments and the absence of notes).

 

    8

     

    

 

(f)  
Taxes. Except as set forth in Schedule 4.6:

 

(i)
All material Tax Returns required to have been filed
by GSP Nutrition has been filed, and each such Tax Return reflects the liability for Taxes in all material respects. All Taxes shown
on such Tax Returns as due have been paid or accrued.

 

(ii)   
To the actual knowledge of the GSP Shareholders, there
is no audit pending against GSP Nutrition in respect of any Taxes. There are no liens on any of the assets of GSP Nutrition that arose
in connection with any failure (or alleged failure) to pay any Tax, other than liens for Taxes not yet due and payable.

 

(iii)    
GSP Nutrition has withheld and paid or accrued for all
material Taxes required to have been withheld and paid or accrued for in connection with amounts paid or owing to any third party.

 

(iv)
GSP Nutrition has not waived any statute of limitations
in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency.

 

(v)
GSP Nutrition is not a party to any Tax allocation or
sharing agreement.

 

(g)
Compliance with Laws and Orders; Permits.

 

(i)
To the actual knowledge of the GSP Shareholders, GSP
Nutrition is in compliance with all laws and orders to which the businesses of GSP Nutrition are subject, except where such failure to
comply would not reasonably be expected to have, individually or in the aggregate, a GSP Material Adverse Effect.

 

(ii)   
GSP Nutrition owns, holds, possesses, or lawfully uses
in the operation of their businesses all permits that are necessary for it to conduct its businesses as now conducted, except where such
failure to own, hold, possess or lawfully use such Permit would not reasonably be expected to have, individually or in the aggregate,
a GSP Material Adverse Effect.

 

(h)
No Undisclosed Liabilities. GSP Nutrition does
not have any liabilities, except for (a) liabilities set forth in the Interim Financial Statements, (b) liabilities which have arisen
since the date of the Interim Financial Statements in the ordinary course of business, or (c) liabilities arising in connection with
the transactions contemplated thereby.

 

(i)
Real Property. GSP Nutrition does not own or
lease any real property.

 

    9

     

    

 

(j)
 ABG-SI License Agreement.

 

(i)
Except as set forth on Schedule 4.10, neither GSP Nutrition
nor, to the actual knowledge of the GSP Shareholders, the other parties to the ABG-SI License Agreement are in default in the performance,
observance or fulfillment of any obligation, covenant or condition contained in the ABG-SI License Agreement.

 

(ii)   
The ABG-SI License Agreement is a legal, valid and binding
obligation of the parties thereto, enforceable against each party thereto in accordance with its terms, except as limited by (i) bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws relating to creditors’ rights generally and
(ii) general principles of equity, whether such enforceability is considered in a proceeding in equity or at law. The ABG-SI License
Agreement is in full force and effect.

 

(k)
Contracts. Except for the ABG-SI License Agreement
or as set forth on Schedule 4(k), as of the date hereof, GSP Nutrition is not a party to or bound by any: (i) contract not contemplated
by this Agreement that materially limits the ability of GSP Nutrition to engage or compete in any manner, of the businesses presently
conducted by GSP Nutrition or the Company; (ii) contract that creates a partnership or joint venture or similar arrangement with respect
to any material businesses of the Company; (iii) indenture, credit agreement, loan agreement, security agreement, guarantee, note, mortgage
or other evidence of indebtedness or agreement providing for indebtedness for borrowed money in excess of $25,000; (iv) contract that
relates to the acquisition or disposition of any material business (whether by merger, sale of equity, sale of assets or otherwise) other
than this Agreement; or (v) contract that involves performance of services or delivery of goods or materials by or to GSP Nutrition in
an amount or with a value in excess of $25,000.

 

(l)
Legal Proceedings. There are no claims, actions,
causes of action, demands, lawsuits, arbitrations, inquiries, audits, notices of violation, proceedings, litigation, citations, summons,
subpoenas, or investigations of any nature, whether at law or in equity pending or, to the actual knowledge of the GSP Shareholders,
threatened against or by GSP Nutrition.

 

(m)
Brokers’ and Finders’ Fees. GSP Nutrition
has not incurred, nor will the GSP Nutrition incur, directly or indirectly, any liability for brokerage or finders’ fees or agents’
commissions or any similar charges in connection with this Agreement or the transactions contemplated hereby.

 

(n)
Inventory. All Inventory is owned by GSP Nutrition,
and, to the actual knowledge of the GSP Shareholders, all such inventory consists of a quality and quantity usable and salable for sale
in the ordinary course of business at customary gross margins, except for any inventory that is obsolete, discontinued, damaged, or of
below standard quality or merchantability that has been written down to realizable fair market value on the Financial Statements. To
the actual knowledge of the GSP Shareholders, none of such inventory is obsolete, discontinued, damaged, overage, or of below standard
quality or merchantability, except for items that have been written down to realizable market value on the Financial Statements.

 

    10

     

    

 

5.
 Representations and Warranties of the Company.
The Company hereby represents and warrants to the GSP Shareholders as of the date hereof and as of the Closing Date as follows:

 

(a)
Organization; Authority; Binding Agreement. The
Company is a corporation duly organized and validly existing under the laws of the State of Delaware. The execution, delivery and performance
by the Company of this Agreement and any other document being delivered by the Company pursuant to this Agreement have been duly authorized
by all necessary corporate action. This Agreement is a valid and binding agreement of the Company, enforceable against the Company in
accordance with its terms, except as may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization or similar laws
affecting creditors’ rights generally or by general equitable principles and except insofar as the enforceability of any provision
of such agreement would be restricted or void by reason of public policy.

 

(b)
Non-contravention. The execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby will not (i) violate any agreement or contract to which
the Company is a party or by which the Company is bound (or the organizational documents of the Company), or any applicable law of any
governmental entity having jurisdiction over the Company or any order, judgment or decree applicable to the Company or (ii) result in
the creation or imposition of any encumbrance on any assets of the Company.

 

(c)
No Consents. Assuming the accuracy of the representations
and warranties made by the GSP Shareholders in Section 3, no notice to, filing with, or authorization, registration, consent or approval
of any governmental entity or other Person is necessary for the execution, delivery or performance by the Company of this Agreement or
the consummation of the transactions contemplated hereby, except for filings, if any, pursuant to Regulation D of the Securities Act
and applicable state securities laws.

 

(d)
Capitalization; Issuance of Estimated Aggregate Company
Share Issuance. Immediately following the consummation of the GSP Contribution Transactions, the capitalization of the Company shall
be as set forth on Schedule 5(d) to the Agreement. When issued and delivered in accordance with this Agreement, the Company Common Stock
issued to the GSP Shareholders will be validly issued and nonassessable, free and clear of all preemptive rights and any other Encumbrances.

 

(e)
Subsidiaries. Immediately following the consummation
of the GSP Contribution Transactions, the Company shall own, directly or indirectly, the percentage of each of the entities set forth
on Schedule 5(e) hereto (each, a “Company Subsidiary”). Except for the Company Subsidiaries listed on Schedule 5(e),
the Company does not own, directly or indirectly (including through any Company Subsidiary), any ownership interest in or to any other
Person.

 

(f)
  Brokers’ and Finders’
Fees. The Company has not incurred, nor will the Company incur, directly or indirectly, any liability for brokerage or
finders’ fees or agents’ commissions or any similar charges in connection with this Agreement or the transactions
contemplated hereby.

 

(g)
Legal Proceedings. Except as set forth on Schedule
5(g), there are no claims, actions, causes of action, demands, lawsuits, arbitrations, inquiries, audits, notices of violation, proceedings,
litigation, citations, summons, subpoenas, or investigations of any nature, whether at law or in equity pending or threatened against
or by the Company or any of its subsidiaries.

 

    11

     

    

 

6.
Covenants.

 

(a)
Conditions. Each of the Company and the GSP Shareholders
shall use their commercially reasonable efforts to cause the conditions set forth in this Agreement to be satisfied and to consummate
the transactions contemplated herein as soon as practicable after the date hereof.

 

(b)
Further Actions. If at any time after the Closing,
the Company shall consider or be advised that any further assignments, conveyances, transfers, or any other similar actions or things,
may be necessary or appropriate to transfer to the Company any right, title or interest of the GSP Shareholders in or to the Outstanding
GSP Shares, each of the GSP Shareholders agrees to promptly execute, deliver and record, or cause to be executed, delivered and recorded,
any and all such further instruments of assignment, conveyance and transfer and take, or cause to be taken, all actions and do, or cause
to be done, all things, as may be reasonably requested by the Company to transfer to the Company all right, title and interest of the
GSP Shareholders in and to the Outstanding GSP Shares.

 

(c)
ABG-SI License Fees. Concurrently with the Closing,
the Company shall, or shall cause GSP Nutrition to, pay the outstanding license fees due and owing to ABG-SI, LLC by GSP Nutrition pursuant
to that certain License Agreement, effective as of June 1, 2020 and as amended (the “ABG-SI License Agreement”), by
and between ABG-SI, LLC and GSP Nutrition.

 

(d)
Releases of GSP Shareholders. Effective as of
the Closing, each GSP Shareholder, on such GSP Shareholder’s own behalf, hereby forever releases, remises and discharges GSP Nutrition
and each of its officers, directors and employees (collectively, the “Released Parties”) from any and all claims,
demands, controversies, actions, causes of action, obligations, liabilities, costs, expenses, fees and damages whatsoever in character,
nature and kind, at law or in equity which such GSP Shareholder now has, had ever had or may hereafter have against GSP Nutrition or
any of the other Released Parties arising from conduct occurring on or prior to the Closing Date. Each GSP Shareholder hereby irrevocably
covenants to refrain from, directly or indirectly, asserting any claim, or commencing, instituting or causing to be commenced, any proceeding
of any kind against any of the Released Parties, based upon any matter purported to be released hereby.

 

    12

     

    

 

(e) Operation
of the Company’ Business. During the period commencing on the date hereof and ending at the earlier of the Closing and the
termination of this Agreement in accordance with Section 8(c), GSP Nutrition, except (i) as otherwise contemplated by this
Agreement, (ii) as required by applicable law or (iii) with the prior written consent of the Company (which consent will not be
unreasonably withheld, conditioned, or delayed), shall:

 

(i)
use commercially reasonable efforts to carry on its
business in a manner consistent with past practice and refrain from extraordinary transactions;

 

(ii)   
use commercially reasonable efforts to maintain the
properties and other assets of the GSP Nutrition in good working order (normal wear excepted); and

 

(iii)    
use GSP Nutrition’s commercially reasonable efforts
to maintain its business and employees, customers, assets and operations as a going concern and in accordance with past practice.

 

(f)  
Access. During the period commencing on the date
hereof and ending at the earlier of the Closing and the termination of this Agreement in accordance with Section 8(c), GSP Nutrition
will provide reasonable access to its financial, accounting, business records, contracts and other legal documents maintained by it for
the purpose of the Company completing its due diligence investigation. The Company shall not contact or communicate with any of GSP Nutrition’s
employees, customers, suppliers or advisors without the prior written consent of GSP Nutrition and in the presence of the GSP Nutrition’s
management. The parties hereto will cooperate to complete due diligence in a reasonably expeditious timeframe.

 

(g)
Notice of Developments. The GSP Shareholders
and GSP Nutrition will give prompt written notice to the Company of any event that would reasonably be expected to give rise to, individually
or in the aggregate, a GSP Material Adverse Effect or would reasonably be expected to cause a breach of any of their respective representations,
warranties, covenants or other agreements contained herein. The Company will give prompt written notice to GSP Nutrition of any event
that could reasonably be expected to cause a breach of any of its representations, warranties, covenants or other agreements contained
herein or could reasonably be expected to, individually or in the aggregate, prevent or materially delay the consummation of the transactions
contemplated by this Agreement. Except as set forth below, the delivery of any notice pursuant to this Section 6(g) will not limit, expand
or otherwise affect the remedies available hereunder (if any) to the party receiving such notice; provided, however, if GSP Nutrition
provides notice of any such GSP Material Adverse Effect or breach of this Agreement pursuant to this Section 6(g) and the Company
elects to consummate the Closing notwithstanding such GSP Material Adverse Effect or breach, the GSP Shareholders shall have no liability
under this Agreement arising out of such GSP Material Adverse Effect or breach.

 

(h)
No Solicitation.

 

(i)
Each of the GSP Shareholders and GSP Nutrition will
and will cause each of their Representatives to cease immediately any existing discussions regarding a Transaction Proposal.

 

    13

     

    

 

(ii)
  During the period commencing on the date
hereof and ending at the earlier of the Closing and the termination of this Agreement in accordance with Section 8(c), without the
prior consent of the Company, GSP Nutrition shall not, nor will it authorize or permit any of its Representatives, including,
without limitation, any GSP Shareholder to, directly or indirectly through another Person to, (i) solicit, initiate or encourage
(including by way of furnishing information), or take any other action designed to facilitate any inquiries, proposals or offers
from any Person that constitute, or would reasonably be expected to constitute, a Transaction Proposal, (ii) participate in any
discussions or negotiations (including by way of furnishing information) regarding any Transaction Proposal or (iii) otherwise
cooperate in any way with, or assist or participate in, facilitate or encourage, any effort or attempt by any other Person to do or
seek any of the foregoing. GSP Nutrition shall immediately communicate to the Company the terms of any Transaction Proposal received
by any of the GSP Shareholders or GSP Nutrition, or any of their Representatives.

 

(i)
Financial Information. GSP Nutrition shall reasonably
cooperate with the Company and the Company’s independent certified public accounting firm, in order to enable the Company to create
audited financial statements prepared in accordance with GAAP for the two full fiscal years preceding the Closing Date by making available
GSP Nutrition’s records as they are maintained in the ordinary course of business and answering reasonable questions.

 

(j)
Confidentiality. Except as otherwise required
by applicable law, each of the parties executing this Agreement will treat and hold as confidential all of the other party’s Confidential
Information (as defined below), refrain from disclosing any of the Confidential Information except in connection with the transactions
contemplated hereby, and deliver promptly to the other party or destroy, at the request and option of the other party, all tangible embodiments
(and all copies) of the other party’s Confidential Information which are in its possession. Notwithstanding the foregoing, either
party may disclose the other party’s Confidential Information to its employees, directors, attorneys, accountants, investors or
prospective investors and other representatives who have a need to know such Confidential Information in order to enable the disclosing
party to use such Confidential Information for purposes permitted in this summary of terms provided such representatives agree to be
bound to use and disclose such Confidential Information for no other purpose. Each party shall take such steps as are required to insure
the confidentiality of Confidential Information used by its representatives. For purposes of this summary of terms, “Confidential
Information” means with respect to a party, any information concerning the organization, business or finances of such party, or
of any third party that such party is under an obligation to keep confidential that is maintained by such party as confidential, and
that is not available to the party from public or other sources. Confidential Information includes, but is not limited to, trade secrets
or confidential information respecting inventions, products, designs, methods, know-how, show-how, techniques, systems, models, algorithms,
processes, software programs, works of authorship, customer lists, projects, plans and proposals. From and after the Closing Date, this
Section 6(k) shall no longer apply to the Company in respect of GSP Nutrition and, prior to the Closing Date, the Company shall be permitted
to disclose Confidential Information as required by applicable federal securities laws in connection with the filing of a registration
statement by the Company with the SEC.

 

(k) Disclosure
Schedule. The parties acknowledge and agree that (i) none of the Company nor the GSP Shareholder and GSP Nutrition have yet
delivered a definitive disclosure schedules to this Agreement to the other parties, and (ii) none of the parties has been provided
with copies of, nor had an opportunity to review, the items to be referred to on the disclosure schedules once delivered. Each of
the parties shall deliver to the other parties the respective schedules to the Agreement, and documents referred to thereon, in
final form within 7 days of the date hereof. The parties shall have 7 days following delivery of such schedules and such documents
in which to terminate this Agreement if no party objects to any information contained in such schedules or the contents of any such
document and parties cannot agree on mutually satisfactory modifications thereto.

 

    14

     

    

 

7.
Conditions to Closing.

 

(a)
Conditions to the Company’s Obligations.
The obligations of the Company to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment (except
to the extent waived in writing by the Company) at or prior to Closing of the following conditions:

 

(i)
Each of the representations and warranties made by the
GSP Shareholders in Section 3 of this Agreement shall be true and correct in all respects as of the Closing Date. The GSP Shareholders
shall have performed in all material respects and complied in all material respects with all agreements and conditions contained in this
Agreement that are required to be performed or complied with by them prior to or at the Closing;

 

(ii)   
All authorizations, consents, orders, declarations or
approvals of, or filings with, or terminations or expirations of waiting periods imposed by, any Governmental Entity with respect to
the transactions contemplated by this Agreement shall have been obtained or made, as applicable, and shall be in full force and effect;

 

(iii)    
GSP Nutrition shall have delivered the consent of ABG-SI,
LLC to the assignment of the ABG-SI License Agreement (the “ABG-SI Consent”), which ABG-SI Consent shall be conditioned
upon payment of the outstanding license fees due and owing to ABG-SI, LLC concurrently with the Closing as contemplated by Section
6(c) above.

 

(iv)
Each GSP Shareholder shall have delivered to the Company
certificates, if any, representing the Outstanding GSP Shares owned by such GSP Shareholder, duly endorsed in blank or with stock powers
duly endorsed in blank, in proper form for transfer, with all appropriate stock transfer tax stamps affixed;

 

(v)
The Company shall have received resignations effective
immediately upon Closing of the directors and officers of GSP Nutrition set forth on Schedule 6.1(e);

 

(vi)
Any and all options and warrants to purchase capital
stock of GSP Nutrition shall have been cancelled, and the GSP Stockholders shall have delivered to the Company evidence (satisfactory
to the Company) of cancellation of any such options and warrants;

 

(vii)   
The Company shall have completed its business, accounting
and legal due diligence review of the GSP Nutrition, its assets and liabilities, and the results thereof shall be reasonably satisfactory
to the Company.

 

    15

     

    

 

(viii)  
 There shall not have been any occurrence, event, incident,
action, failure to act, or transaction since the date of the Interim Financial Statements, which has had or is reasonably likely to cause
a GSP Material Adverse Effect.

 

(ix)
GSP Nutrition shall have delivered evidence reasonably
satisfactory to the Company of its organization and proceedings and its existence in the jurisdiction in which it is formed, including
evidence of such existence as of the Closing.

 

(b)
Conditions to the GSP Shareholders’ Obligations.
The obligations of the GSP Shareholders to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment
(except to the extent waived in writing by the GSP Shareholders) at or prior to Closing of each of the following conditions:

 

(i)
Each of the representations and warranties made by the
Company in Section 5 of this Agreement shall be true and correct in all respects as of the Closing Date. The Company shall have
performed in all material respects and complied in all material respects with all agreements and conditions contained in this Agreement
that are required to be performed or complied with by it prior to or at the Closing;

 

(ii)   
All authorizations, consents, orders, declarations or
approvals of, or filings with, or terminations or expirations of waiting periods imposed by, any Governmental Entity with respect to
the transactions contemplated by this Agreement shall have been obtained or made, as applicable, and shall be in full force and effect;
and

 

(iii)    
The Company shall have delivered to each GSP Shareholder
stock certificates representing the number of shares of Company Common Stock set forth opposite such GSP Shareholder’s name on
Schedule B hereto.

 

8.
Miscellaneous.

 

(a)
Survival; Limitations on Liability. The representations
and warranties of the parties hereto contained in this Agreement shall survive the Closing for a period of twenty-four (24) months. The
covenants and agreements of the parties hereto contained in this Agreement shall survive the Closing indefinitely.

 

No
GSP Shareholder shall be responsible for, or have any liability with respect to, any breach by any other GSP Shareholder of the
representations and warranties made by such other GSP Shareholder pursuant to Section 3 of this Agreement. Each Specific GSP
Shareholder shall only be responsible for such Specific GSP Shareholder’s Percentage Interest of any losses or damages arising
from a breach of any of the representations and warranties of Section 4 of this Agreement. The non-Specific GSP Shareholders shall
not be responsible or liable for any breaches of any of the representations and warranties of Section 4 of this Agreement. The
aggregate liability of a GSP Shareholder for breaches of the representations and warranties of Section 3 and 4 hereof shall be, (i)
in the case of the non-GSP Fundamental Representations, twenty-five percent (25%) of the Purchase Price received by such GSP
Shareholder in shares of Company Common Stock and (ii) in the case of the GSP Fundamental Representations (but subject to the first
sentence of this paragraph and, in the case of the non-Specific GSP Shareholders, the third sentence of this paragraph), one hundred
percent (100%) of the Purchase Price received by such GSP Shareholder in shares of Company Common Stock. Notwithstanding anything
contained herein to the contrary, the aggregate liability of a GSP Shareholder under this Agreement shall not exceed the Purchase
Price received by such GSP Shareholder in shares of Company Common Stock. If any damages or losses are determined to be due and
owing by any GSP Shareholder for a breach of this Agreement, such GSP Shareholder shall have the right, in such GSP
Shareholder’s sole discretion, to satisfy such damages or losses either (i) in cash or (ii) in shares of Company Common Stock
received pursuant to this Agreement, which shares shall be valued at the IPO PPS.

 

    16

     

    

 

(b)
Amendments. This Agreement may be amended, modified,
or supplemented only pursuant to a written instrument making specific reference to this Agreement and signed by the Company and the GSP
Shareholders holding a majority of the Outstanding GSP Shares.

 

(c)
Termination. This Agreement shall terminate and
be of no further force and effect if the Closing has not occurred on or before the sixtieth (60th) day following the date
hereof.

 

(d)
Assignment. Neither this Agreement nor any right
or obligation hereunder shall be assigned, delegated, or otherwise transferred (whether voluntarily, by operation of law, by merger,
or otherwise) by the Company, on the one hand, or the GSP Shareholders, on the other hand, without the prior written consent of the other
parties. Any attempted assignment, delegation, or transfer in violation of this Section 8(d) shall be void and of no force or
effect.

 

(e)
Binding Effect. This Agreement shall be binding
upon and shall inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors, and permitted
assigns.

 

(f)  
Construction. The section headings of this Agreement
are for convenience of reference only and shall not be deemed to alter or affect the meaning or interpretation of any provision hereof.
Unless the context otherwise requires, (i) all references to Sections contained in this Agreement are references to sections of this
Agreement, (ii) words in the singular include the plural and vice versa, and (iii) words of any gender include each other gender. As
used in this Agreement the following words or phrases have the following meanings: (i) “hereby”, “herein”, “hereof”,
“hereto”, “hereunder”, and words of similar import refer to this Agreement as a whole and not to any particular
provision hereof; and (ii) “or” means “and/or”.

 

(g)
Counterparts; Electronic Signatures. This Agreement
may be executed in multiple counterparts, each of which when so executed and delivered shall be an original, and all of which when taken
together shall constitute one and the same instrument. Facsimile, .pdf and other electronic signatures to this Agreement shall have the
same effect as original signatures.

 

(h)
Entire Agreement. This Agreement (and the documents
referenced herein) constitute the entire agreement of the parties hereto in respect of the subject matter hereof, and supersedes any
and all prior agreements or understandings between the parties hereto in respect of such subject matter.

 

    17

     

    

 

(i)
 Notices. All notices and other communications
given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt
or: (i) personal delivery to the party to be notified, (ii) when sent, if sent by electronic mail or facsimile during normal business
hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, (iii) five (5)
days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) business day
after deposit with an internationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written
verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature pages
hereto, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this
Section 8(i).

 

(j)
Severability. If any provision of this Agreement
or the application of such provision to any Person or circumstance shall be held by a court of competent jurisdiction to be invalid,
illegal, or unenforceable under the Applicable Law of any jurisdiction, (i) the remainder of this Agreement or the application of such
provisions to other Persons or circumstances or in other jurisdictions shall not be affected thereby, (ii) such invalid, illegal, or
unenforceable provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such Applicable Law, and (iii) such invalid, illegal, or unenforceable provision shall not affect the validity or enforceability
of any other provision of this Agreement.

 

(k)
No Third-Party Beneficiaries. Nothing express
or implied in this Agreement is intended or shall be construed to confer upon or give any Person other than the parties hereto and their
respective heirs, successors, and permitted assigns any right, benefit, or remedy under or by reason of this Agreement.

 

(l)
No Waiver. No waiver of any provision hereof,
or consent required hereunder, or any consent or departure from this Agreement, shall be valid or binding unless expressly and affirmatively
made in writing and duly executed by the party to be charged with such waiver. No waiver shall constitute or be construed as a continuing
waiver or a waiver in respect of any subsequent default, either of similar or different nature, unless expressly so stated in such writing.

 

(m)
Governing Law. This Agreement shall be enforced,
governed, and construed in all respects in accordance with the laws of the State of Delaware applicable to contracts executed and performable
in such State.

 

(n)
Jurisdiction; Venue. Any dispute regarding the
interpretation or validity of, or otherwise arising out of or relating to, this Agreement or the transactions contemplated hereby shall
be subject to the jurisdiction of either the federal or state court sitting in the State of Delaware sitting in the County of New Castle.
Each party hereto hereby submits to the personal and exclusive jurisdiction and venue of such courts (and of the appropriate appellate
courts therefrom) in any such dispute and irrevocably waives, to the fullest extent permitted by law, any objection that it may now or
hereafter have to the laying of the venue of any such dispute in any such court or that any such dispute that is brought in any such
court has been brought in an inconvenient forum.

 

    18

     

    

 

(o)
 Undisclosed Capital Stock of GSP Shareholders.
Each GSP Shareholder acknowledges and agrees that, to the extent such GSP Shareholder owns any shares of capital stock or other equity
interests (or any options, rights or warrants to purchase shares of capital stock or other equity interests) of GSP Nutrition that are
not set forth on Schedule A hereto (“Undisclosed GSP Equity”), such GSP Shareholder is selling, transferring,
conveying and assigning such Undisclosed GSP Equity to the Company on the Closing Date.

 

(p)
Transfer Taxes. The Company shall be responsible
for all transfer taxes associated with the transactions contemplated by this Agreement.

 

    19

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Contribution and Exchange Agreement to be duly and validly executed as of the date
first set forth above.

 

	 	COMPANY:
	 	SMART
    FOR LIFE, INC.
	 	          
	 	By:	/s/
    Alfonso J. Cervantes         
	 	 	Name:	Alfonso
    J. Cervantes    
	 	 	Title:	Executive
    Chairman

 

	 	Address:	         
	 	 	
	 	 	
	 	 	 
	 	with
    a copy to (which shall not constitute notice):
	 	 
	 	Bevilacqua
    PLLC
	 	1050
    Connecticut Avenue, NW
	 	Suite
    500
	 	Washington,
    D.C. 20036
	 	Attention:
    Louis A. Bevilacqua
	 	Email:

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Contribution and Exchange Agreement to be duly and validly executed as of the date
first set forth above.

 

	 	GSP
    NUTRITION, INC.:
	 	 
	 	By:	/s/
    Stuart Benson
	 	 	Name: 	Stuart
    Benson
	 	 	Title:	Co-Chairman

 

	 	Address:	                           
	 	 	 
	 	 	 
	 	 	 
	 	with
    a copy to (which shall not constitute notice):
	 	 
	 	Greenberg
    Traurig, P.A.
	 	401
    E. Las Olas Boulevard, Suite 2000
	 	Fort
    Lauderdale, FL 33301
	 	Attention:
    Mathew Hoffman
	 	Email:
    hoffmanma@gtlaw.com

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Contribution and Exchange Agreement to be duly and validly executed as of the date
first set forth above.

 

	 	GSP SHAREHOLDERS:
	 	 
	 	SIGROUP
    VENTURES, LLC
	 	                       
	 	By: 	/s/
    Stuart Benson                 
	 	Name:	Stuart Benson
	 	Title:	Managing Member

 

	 	Address:	 
	 	 	 
	 	 	

 

	 	SGSP
    INC.
	 	 	 
	 	By:	/s/
    Joshua Lamstein
	 	Name:	Joshua
    Lamstein
	 	Title:	Chairman

 

	 	Address:	 
	 	 	 
	 	 	

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Contribution and Exchange Agreement to be duly and validly executed as of the date
first set forth above.

 

	 	GSP
    SHAREHOLDERS:
	 	 
	 	EXECUTIVE
    DIRECT, INC.
	 	 	 
	 	By:	/s/
    Jason Provenzano
	 	Name:	Jason
    Provenzano
	 	Title:	President

 

	 	Address:	       
	 	 	 
	 	 	
	 	 	 
	 	/s/
    Stuart Benson
	 	Stuart
    Benson

 

	 	Address:	 
	 	 	 
	 	 	 

  

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Contribution and Exchange Agreement to be duly and validly executed as of the date
first set forth above.

 

	 	GSP
    SHAREHOLDERS:
	 	 
	 	NUTRAGLOBAL,
    LLC
	 	 	 
	 	By:	/s/
    Stuart Benson                 
	 	Name:	Stuart
    Benson
	 	Title:	Managing
    Member

 

	 	Address:	       
	 	 	 
	 	 	 
	 	 	 

 

	 	HAYES
    FAMILY TRUST
	 	 	 
	 	By:	/s/
    Donald L. Hayes            
	 	Name:	Donald
    L. Hayes
	 	Title:	Trustee

 

	 	Address:	 
	 	 	 
	 	 	

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Contribution and Exchange Agreement to be duly and validly executed as of the date
first set forth above.

 

	 	GSP
    SHAREHOLDERS:
	 	 
	 	PALMERHOUSE
    FREESTYLE FUND 1 LLC
	 	 	 
	 	By:	/s/
    Robert Greenspan              
	 	Name:	Robert
    Greenspan
	 	Title:	Manager

 

	 	Address:	       
	 	 	 
	 	 	 

 

	 	NU
    VIEW TRUST COMPANY CUSTODIAN FBO MICHAEL GREENSPAN IRA
	 	 	 
	 	By:	/s/
    Glen Mather     
	 	Name:	Glen
    Mather
	 	Title:	Authorized
    Signer

 

	 	Address:	 
	 	 	 
	 	 	

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Contribution and Exchange Agreement to be duly and validly executed as of the date
first set forth above.

 

	 	GSP
    SHAREHOLDERS:
	 	 
	 	HCFP/CAPITAL
    PARTNERS 36B-4 LLC
	 	 	 
	 	By:	/s/
    Anthony Dubreville                 
	 	Name:	Anthony
    Dubreville
	 	Title:	Manager

 

	 	Address:	 
	 	 	 
	 	 	

 

	 	HCFP/DIRECT
    INVESTMENTS LLC
	 	 	 
	 	By:	/s/
    Joshua Lamstein             
	 	Name:	Joshua
    Lamstein
	 	Title:	Manager

 

	 	Address:	
	 	 	
	 	 	

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Contribution and Exchange Agreement to be duly and validly executed as of the date
first set forth above.

 

	 	GSP
    SHAREHOLDERS:
	 	 
	 	MAKERS
    NUTRITION
	 	 	 
	 	By:	/s/
    Jason Provenzano
	 	Name:	Jason
    Provenzano
	 	Title:	President/CEO

 

	 	Address:	 
	 	 	 
	 	 	

 

	 	DUBREVILLE
    FAMILY TRUST, 7/1/97, ANTHONY M. DUBREVILLE, TRUSTEE
	 	 	 
	 	By:	/s/
    Anthony Dubreville
	 	Name:	Anthony
    Dubreville
	 	Title:	Trustee

 

	 	Address:	 
	 	 	 
	 	 	

     

     

    

IN
WITNESS WHEREOF, the parties hereto have caused this Contribution and Exchange Agreement to be duly and validly executed as of the date
first set forth above.

 

	 	GSP
    SHAREHOLDERS:
	 	 
	 	/s/
    Robert Bernstein
	 	Dr.
    Robert Bernstein
	 	 
	 	Address:	                               
	 	 	 
	 	 	 
	 	 	 
	 	/s/
    Seth D. Moskowitz
	 	Seth
    D. Moskowitz
	 	 	 
	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	/s/
    Jaren Toren
	 	Jared
    Toren
	 	 	 
	 	Address:	 
	 	 	 
	 	 	 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Contribution and Exchange Agreement to be duly and validly executed as of the date
first set forth above.

 

	 	GSP
    SHAREHOLDERS:
	 	 
	 	JOSHUA
    R. LAMSTEIN C/F RUBY LAMSTEIN – UTMA/NY
	 	 	 
	 	By:	/s/
    Joshua Lamstein                 
	 	Name:	Joshua
    Lamstein
	 	Title:	Custodian

 

	 	Address:	 
	 	 	 
	 	 	 

 

	 	JOSHUA
    R. LAMSTEIN C/F NICO LAMSTEIN – UTMA/NY
	 	 	 
	 	By:	/s/
    Joshua Lamstein       
	 	Name:	Joshua
    Lamstein
	 	Title:	Custodian

 

	 	Address:	 
	 	 	 
	 	 	 
	 	 	 

	 	JOSHUA
    R. LAMSTEIN C/F GOLDIE LAMSTEIN – UTMA/NY
	 	 	 
	 	By:	/s/
    Joshua Lamstein
	 	Name:	Joshua
    Lamstein
	 	Title:	Custodian

 

	 	Address:	 
	 	 	 
	 	 	

 

     

     

    

 

Schedule
A

 

	GSP Shareholder	 	Number of Shares

 of GSP Nutrition	 
	HCFP/Capital Partners 36B-4 LLC	 	 	1,000,000	 
	Stuart Benson	 	 	775,376	 
	Executive Direct, Inc.	 	 	2,000,000	 
	SGSP Inc.	 	 	3,702,676	 
	Nutraglobal, LLC	 	 	250,000	 
	Robert Bernstein	 	 	200,000	 
	Dubreville Family Trust, 7/1/97, Anthony M. Dubreville, Trustee	 	 	100,000	 
	Hayes Family Trust	 	 	100,000	 
	Seth D. Moskowitz	 	 	48,895	 
	Jared Toren	 	 	50,000	 
	SIGROUP Ventures, LLC	 	 	4,000,000	 
	Palmerhouse Freestyle Fund 1 LLC	 	 	25,000	 
	Nuview Trust Company Custodian FBO Michael Greenberg IRA	 	 	25,000	 
	HCFP/Direct Investments LLC	 	 	15,000	 
	Joshua R. Lamstein C/F Ruby Lamstein – UTMA/NY	 	 	10,000	 
	Joshua R. Lamstein C/F Nico Lamstein – UTMA/NY	 	 	10,000	 
	Joshua R. Lamstein C/F Goldie Lamstein – UTMA/NY	 	 	10,000	 
	Makers Nutrition	 	 	200,000	 

 

     

     

    

 

Schedule
B

 

	GSP Shareholder	 	Company

 Common Stock	 
	HCFP/Capital Partners 36B-4 LLC	 	 	3,394	 
	Stuart Benson	 	 	2,632	 
	Executive Direct, Inc.	 	 	6,788	 
	SGSP Inc.	 	 	12,567	 
	Nutraglobal, LLC	 	 	848	 
	Robert Bernstein	 	 	679	 
	Dubreville Family Trust, 7/1/97, Anthony M. Dubreville, Trustee	 	 	339	 
	Hayes Family Trust	 	 	339	 
	Seth D. Moskowitz	 	 	166	 
	Jared Toren	 	 	170	 
	SIGROUP Ventures, LLC	 	 	13,576	 
	Palmerhouse Freestyle Fund 1 LLC	 	 	85	 
	Nuview Trust Company Custodian FBO Michael Greenberg IRA	 	 	85	 
	HCFP/Direct Investments LLC	 	 	51	 
	Joshua R. Lamstein C/F Ruby Lamstein – UTMA/NY	 	 	34	 
	Joshua R. Lamstein C/F Nico Lamstein – UTMA/NY	 	 	34	 
	Joshua R. Lamstein C/F Goldie Lamstein – UTMA/NY	 	 	34	 
	Makers Nutrition	 	 	679Exhibit 10.11

 

SECURITIES PURCHASE AGREEMENT

 

dated as of July 21, 2021

 

among

 

BONNE SANTÉ GROUP, INC.,

 

NEXUS OFFERS, INC.,

 

AND

 

JUSTIN FRANCISCO 

 

AND

 

STEVEN RUBERT

 

     

     

    

 

TABLE
OF CONTENTS

 

	 ARTICLE I DEFINITIONS 	1
	 	 	 	 
	 	1.1	Certain Definitions.	1
	 	 	 	 
	ARTICLE II PURCHASE AND SALE OF THE SECURITIES	5
	 	 
	 	2.1	Purchase and Sale of the Securities.	5
	 	2.2	Adjustments to Purchase Price.	5
	 	2.3	Closing.	7
	 	2.4	Transactions to be Effected at the Closing.	7
	 	 	 	 
	ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE SELLER 	8
	 	 	 	 
	 	3.1	Authority and Enforceability.	8
	 	3.2	Noncontravention.	8
	 	3.3	The Securities.	8
	 	3.4	Brokers’ Fees.	9
	 	3.5	Investment Representations.	9
	 	 	 	 
	ARTICLE IV REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANIES 	10
	 	 	 	 
	 	4.1	Organization, Qualification and Corporate Power; Authority and Enforceability.	10
	 	4.2	Subsidiaries.	10
	 	4.3	Capitalization.	10
	 	4.4	Noncontravention.	11
	 	4.5	Financial Statements.	11
	 	4.6	Taxes.	12
	 	4.7	Compliance with Laws and Orders; Permits.	12
	 	4.9	Tangible Personal Assets.	12
	 	4.10	Real Property.	13
	 	4.11	Intellectual Property.	13
	 	4.12	Absence of Certain Changes or Events.	14
	 	4.13	Contracts.	15
	 	4.14	Litigation	16
	 	4.15	Employee Benefits.	16
	 	4.16	Labor and Employment Matters.	16
	 	4.17	Environmental.	16
	 	4.18	Insurance.	16
	 	4.19	Brokers’ Fees.	17
	 	4.20	Certain Business Relationships with the Companies.	17
	 	4.21	Equipment.	17
	 	4.22	Customers and Suppliers.	17
	 	4.23	Potential Conflicts of Interest.	17
	 	4.24	Bank Accounts	18
	 	4.25	Accounts Receivable	18
	 	4.26	Disclosure.	18

 

    i

     

    

 

TABLE
OF CONTENTS

 

	ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE BUYER 	18
	 	 	 	 
	 	5.1	Organization.	18
	 	5.2	Authorization.	18
	 	5.3	Noncontravention.	19
	 	5.4	Litigation	19
	 	5.5	Brokers’ Fees	19
	 	 	 	 
	ARTICLE VI COVENANTS 	20
	 	 	 	 
	 	6.1	Consents.	20
	 	6.2	Operation of the Companies’ Business.	20
	 	6.3	Access.	21
	 	6.4	Notice of Developments.	21
	 	6.5	No Solicitation.	22
	 	6.6	Taking of Necessary Action; Further Action.	22
	 	6.7	Covenant not to Compete.	22
	 	6.8	Financial Information.	23
	 	6.9	Transfer of Cash and Cash Equivalents.	23
	 	6.10	Company Disclosure Schedule.	23
	 	6.11	Piggyback Registration Rights	23
	 	6.12	Tag Along Rights	24
	 	 	 	 
	ARTICLE VII CONDITIONS TO OBLIGATIONS TO CLOSE 	24
	 	 	 	 
	 	7.1	Conditions to Obligation of the Buyer.	24
	 	7.2	Conditions to Obligation of the Seller.	25
	 	 	 	 
	ARTICLE VIII TERMINATION; AMENDMENT; WAIVER 	27
	 	 	 	 
	 	8.1	Termination of Agreement.	27
	 	8.2	Effect of Termination.	27
	 	8.3	Amendments.	27
	 	8.4	Waiver.	27
	 	 	 	 
	ARTICLE IX INDEMNIFICATION 	28
	 	 	 	 
	 	9.1	Survival.	28
	 	9.2	Indemnification by Seller.	28
	 	9.3	Indemnification by Buyer.	28
	 	9.4	Indemnification Procedure.	29
	 	9.5	Failure to Give Timely Notice.	29
	 	9.6	Limited on Indemnification Obligation.	29
	 	9.7	Payments.	30
	 	9.8	Recoupment under Buyer Notes.	30
	 	 	 	 
	ARTICLE X MISCELLANEOUS 	30
	 	 	 	 
	 	10.1	Press Releases and Public Announcement.	30
	 	10.2	No Third-Party Beneficiaries.	30
	 	10.3	Entire Agreement.	30
	 	10.4	Succession and Assignment.	30
	 	10.5	Construction.	31
	 	10.6	Notices.	31
	 	10.7	Governing Law; Mediation; Arbitration.	32
	 	10.8	Headings.	32
	 	10.9	Severability.	33
	 	10.10	Expenses.	33
	 	10.11	Incorporation of Exhibits and Schedules.	33
	 	10.12	Specific Performance.	33
	 	10.13	Counterparts.	33

 

    ii

     

    

 

SECURITIES PURCHASE AGREEMENT

 

SECURITIES PURCHASE AGREEMENT,
dated as of July 21, 2021 (the “Agreement”), among Bonne Santé Group,
Inc., a Delaware corporation (the “Buyer”), Nexus Offers, Inc.
a Florida limited liability company (the “Company”), and Justin
Francisco and Steven Rubert, as the shareholders of the Company (each,
a “Seller” and together, the “Sellers”).

 

RECITALS

 

A.  The
Sellers are collectively the record and beneficial owners of 100% of the issued and outstanding shares of capital stock of the Company
on a fully-diluted basis (such securities, the “Securities”).

 

B.  The
Sellers desire to sell all of the Securities to the Buyer, and the Buyer desires to purchase the Securities from the Sellers, upon the
terms and subject to the conditions set forth in this Agreement (such sale and purchase of the Securities, the “Acquisition”).

 

AGREEMENT

 

NOW, THEREFORE, in consideration
of the foregoing premises and the respective representations and warranties, covenants and agreements contained herein, the parties hereto
agree as follows:

 

ARTICLE I

DEFINITIONS

 

1.1
Certain Definitions. When used in this Agreement, the following terms will have the meanings assigned to them in this Section 1.1:

 

“Action”
means any claim, action, suit, inquiry, hearing, proceeding or other investigation.

 

“Affiliate”
means, with respect to a Person, any other Person that, directly or indirectly, through one or more intermediaries, Controls, is Controlled
by or is under common Control with, such Person. For purposes of this definition, “Control” (including the terms “Controlled
by” and “under common Control with”) means possession of the power to direct or cause the direction of the
management or policies of a Person, whether through the ownership of stock, as trustee or executor, by Contract or otherwise.

 

“Benefit Plan”
means any “employee benefit plan” as defined in ERISA Section 3(3), including any (a) nonqualified deferred compensation or
retirement plan or arrangement which is an Employee Pension Benefit Plan (as defined in ERISA Section 3(2)), (b) qualified defined contribution
retirement plan or arrangement which is an Employee Pension Benefit Plan, (c) qualified defined benefit retirement plan or arrangement
which is an Employee Pension Benefit Plan (including any Multiemployer Plan (as defined in ERISA Section 3(37)), (d) Employee Welfare
Benefit Plan (as defined in ERISA Section 3(1)) or material fringe benefit plan or program, or (e) stock purchase, stock option, severance
pay, employment, change-in-control, vacation pay, company award, salary continuation, sick leave, excess benefit, bonus or other incentive
compensation, life insurance, or other employee benefit plan, contract, program, policy or other arrangement, whether or not subject to
ERISA, under which any present or former employee of the Company has any present or future right to benefits sponsored or maintained by
the Company or any ERISA Affiliate.

 

    1

     

    

 

“Business Day”
means a day other than a Saturday, Sunday or other day on which banks located in Miami, Florida are authorized or required by Law to close.

 

“Closing Working Capital”
means the difference, as of the Closing Date, between (a) the sum of accounts receivable, inventory, capitalized work in process, prepaid
expenses and other current assets of the Company, which shall be reflected on the Closing Date Balance Sheet, less (b) the accounts payable,
customer deposits, sales taxes payable, and other current liabilities of the Company as reflected on the Closing Date Balance Sheet, in
each case, determined in accordance with GAAP.

 

“Code” means
the Internal Revenue Code of 1986, as amended.

 

“Contract”
means any written agreement, contract, commitment, arrangement or understanding.

 

“ERISA” means
the Employee Retirement Income Security Act of 1974, as amended.

 

“ERISA Affiliate”
means any Person who is, or at any time was, a member of a “controlled group of corporations” within the meaning of Section
414(b) or (c) of the Code and, for the purpose of Section 302 of ERISA and/or Section 412, 4971, 4977, 4980D, 4980E and/or each “applicable
section” under Section 414(f)(2) of the Code, within the meaning of Section 412(n)(6) of the Code that includes, or at any time
included, the Company or any Affiliate thereof, or any predecessor of any of the foregoing.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended.

 

“GAAP” means
United States generally accepted accounting principles.

 

“Governmental Entity”
means any entity or body exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to United
States federal, state or local government or foreign, international, multinational or other government, including any department, commission,
board, agency, bureau, official or other regulatory, administrative or judicial authority thereof.

 

“Independent Accounting
Firm” means any regionally recognized independent registered public accounting firm which has not represented the Company or
the Sellers or any of their Affiliates for the past five years as will be agreed by the Company and the Buyer in writing.

 

“IRS” means
the Internal Revenue Service.

 

“Knowledge of the Sellers”
or any similar phrase means the actual knowledge of the Sellers after due inquiry.

 

    2

     

    

 

“Law” means
any statute, law, ordinance, rule, regulation of any Governmental Entity.

 

“Liability”
means all indebtedness, obligations and other liabilities and contingencies of a Person, whether absolute, accrued, contingent, fixed
or otherwise, or whether due or to become due.

 

“Lien” means,
with respect to any property or asset, any mortgage, lien, pledge, charge, security interest, hypothecation or other encumbrance in respect
of such property or asset.

 

“Material Adverse Effect”
means any material adverse effect on the assets, properties, condition (financial or otherwise), operations of the Company and any of
their Subsidiaries, taken as a whole provided, however, that none of the following shall be deemed (either alone or in combination)
to constitute, and none of the following shall be taken into account in determining whether there has been or may be, a Material Adverse
Effect: (i) the effect of any change that generally affects the United States or foreign economies or securities, financial, banking or
credit markets (including changes in interest or exchange rates) or geopolitical conditions; (ii) the effect of any change that generally
affects any industry in which the Company operates; (iii) the effect of any seasonal changes in the results of operations of the Company
consistent with past practices; (iv) the effect of any changes in applicable Laws; (v) the effect of any change caused by natural
disasters or acts of nature, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening
of any such hostilities, acts of war, sabotage or terrorism or military actions.

 

“Minimum Working Capital
Requirement” means the average monthly working capital for the twelve-month period ended July 31, 2021.

 

“Order” means
any award, injunction, judgment, decree, order, ruling, subpoena or verdict or other decision issued, promulgated or entered by or with
any Governmental Entity of competent jurisdiction.

 

“Permit”
means any authorization, approval, consent, certificate, license, permit or franchise of or from any Governmental Entity of competent
jurisdiction or pursuant to any Law.

 

“Person”
means an individual, a corporation, a partnership, a limited liability company, a trust, an unincorporated association, a Governmental
Entity or any agency, instrumentality or political subdivision of a Governmental Entity, or any other entity or body.

 

“Preliminary Working
Capital” means the difference, as of the Closing Date, between (a) the sum of the accounts receivable, inventory, capitalized
work in process, prepaid expenses and other current assets of the Company, which shall be reflected on the Preliminary Balance Sheet,
less (b) the accounts payable, customer deposits, sales taxes payable, and other current liabilities of the Company as reflected on the
Preliminary Balance Sheet, in each case, determined in accordance with GAAP.

 

“Representatives”
means, with respect to any Person, the respective directors, officers, employees, counsel, accountants and other representatives of such
Person.

 

    3

     

    

 

“Subsidiary”
means, with respect to any Person, any corporation, partnership, joint venture or other legal entity of which such Person (either alone
or through or together with any other Subsidiary), owns, directly or indirectly, more than 50% of the stock or other equity interests,
the holders of which are generally entitled to vote for the election of the board of directors or other governing body of a non-corporate
Person.

 

“Taxes” means
all federal, state, local and foreign income, profits, franchise, gross receipts, environmental, customs duty, capital stock, severance,
stamp, payroll, sales, transfer, employment, unemployment, disability, use, property, withholding, excise, production, value added, occupancy
and other taxes, duties or assessments of any nature whatsoever.

 

“Taxing Authority”
means any Governmental Entity having or purporting to exercise jurisdiction with respect to any Tax.

 

“Tax Returns”
means any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule
or attachment thereto, and including any amendment thereof.

 

“Trailing Twelve Months
Adjusted EBITDA” means the Company’s earnings before (i) interest expense, (ii) tax expense, (iii) depreciation and amortization
expense, (iv) equity based compensation expense, (v) owner’s compensation in excess of $300,000, (vi) non-essential travel and entertainment,
(vii) extraordinary one-time items, and (viii) such other adjustment items as mutually agreed upon by the Buyer and the Sellers for the
twelve-month period prior to July 31, 2021, consistent with the calculation of Trailing Twelve Months Adjusted EBITDA for the period ended
December 31, 2020 as set forth on Exhibit A.

 

“Transaction Proposal”
means any unsolicited written bona fide proposal made by a third party relating to (i) any direct or indirect acquisition or purchase
of all or substantially all assets of the Company, (ii) any direct or indirect acquisition or purchase of a majority of the combined voting
power of the Securities, (iii) any merger, consolidation, business combination, recapitalization, liquidation, dissolution or similar
transaction involving the Company in which the other party thereto or its stockholders will own 51% or
more of the combined voting power of the parent entity resulting from any such transaction, or (iv) any other transaction that is inconsistent
with the intent and purpose of this Agreement.

 

“Transfer Taxes”
means sales, use, transfer, recording, documentary, stamp, registration and stock transfer Taxes and any similar Taxes.

 

“$” means
United States dollars.

 

    4

     

    

 

For purposes of this Agreement, except as otherwise
expressly provided herein or unless the context otherwise requires: (i) the meaning assigned to each term defined herein will be equally
applicable to both the singular and the plural forms of such term and vice versa, and words denoting any gender will include all genders
as the context requires; (ii) where a word or phrase is defined herein, each of its other grammatical forms will have a corresponding
meaning; (iii) the terms “hereof”, “herein”, “hereunder”, “hereby” and “herewith”
and words of similar import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular
provision of this Agreement; (iv) when a reference is made in this Agreement to an Article, Section, paragraph, Exhibit or Schedule without
reference to a document, such reference is to an Article, Section, paragraph, Exhibit or Schedule to this Agreement; (v) a reference to
a subsection without further reference to a Section is a reference to such subsection as contained in the same Section in
which the reference appears, and this rule will also apply to paragraphs and other subdivisions; (vi) the word “include”,
“includes” or “including” when used in this Agreement will be deemed to include the words “without limitation”,
unless otherwise specified; (vii) a reference to any party to this Agreement or any other agreement or document will include such party’s
predecessors, successors and permitted assigns; (viii) a reference to any Law means such Law as amended, modified, codified, replaced
or reenacted as of the date hereof, and all rules and regulations promulgated thereunder as of the date hereof; and (ix) all accounting
terms used and not defined herein have the respective meanings given to them under GAAP.

 

ARTICLE II

PURCHASE AND SALE OF THE SECURITIES

 

2.1
Purchase and Sale of the Securities. Upon the terms and subject to the conditions set forth in this Agreement, the Buyer agrees
to pay to the Sellers for the Securities in the aggregate at the Closing approximately Three Million, Eight Hundred Eighty Thousand Dollars
($3,880,000) (the “Purchase Price”), subject to adjustment as described in Section 2.2 below, by delivery of (i) cash
in the amount of Two Million Dollars ($2,000,000) (the “Cash Portion”), payable by wire transfer or delivery of other
immediately available funds to one or more accounts at banks identified by Sellers to Buyer in writing at least two (2) business days
prior to the Closing Date, (ii) a convertible promissory note (“Buyer Note I”) in a form to be mutually agreed to between
the Buyer and the Sellers in the aggregate principal amount of One Million Dollars ($1,000,000), and (iii) a non-convertible promissory
note (“Buyer Note II,” and together with Buyer Note I the “Buyer Notes”) in the form to be mutually
agreed to in the aggregate principal amount of Eight Hundred Eighty Thousand Dollars ($880,000). The Buyer Notes will each bear interest
at the rate of 5% per annum and will be amortized on a 60-month straight line basis with a balloon payment on the 36th month.
The Buyer Notes will be subordinated to the senior indebtedness of the Buyer and the Company and will have a subordinated security interest
(after the senior secured indebtedness) covering all of the assets of the Company.

 

2.2  Adjustments to Purchase
Price.

 

(a)
Trailing Twelve-Month Adjusted EBITDA Adjustments.

 

(i)
The Purchase Price is based upon a four times (4x) multiple of the Trailing Twelve-Month Adjusted EBITDA. The Buyer has engaged Liggett
and Webb to prepare a quality of earnings report on the Company (the “Quality of Earnings Report”). The Purchase Price
shall be adjusted upwards or downwards upon delivery of the Quality of Earnings Report to all parties based upon the difference between
four times (4x) the Trailing Twelve-Month Adjusted EBITDA as shown in the Quality of Earnings Report and the Purchase Price. The adjusted
Purchase Price shall be allocated among the Cash Portion and the Buyer Notes based on the percentage of the Purchase Price that each such
component of consideration makes up as described above in Section 2.1.

 

    5

     

    

 

(ii)
In the event the Sellers do not agree with the Trailing Twelve-Month Adjusted EBITDA as set forth in the Quality of Earnings Report, the
Sellers shall so inform the Buyer in writing within 20 days of the Sellers’ receipt thereof, such writing to set forth the objections
of the Sellers in reasonable detail. If the Sellers and the Buyer cannot reach agreement as to any disputed matter relating to the Trailing
Twelve-Month Adjusted EBITDA as set forth in the Quality of Earnings Report within 15 days after notification by the Sellers to the Buyer
of a dispute, they shall forthwith refer the dispute to an Independent Accounting Firm mutually agreeable to the Sellers and the Buyer
for resolution, with the understanding that such firm shall resolve all disputed items within 20 days after such disputed items are referred
to it. If the Buyer and the Sellers are unable to agree on the choice of an Independent Accounting Firm, they shall select an Independent
Accounting Firm by lot from up to three firms proposed by each of the Sellers and Buyer (after excluding their respective regular outside
accounting firms). Each of the Sellers and the Buyer shall bear one-half of the costs of such accounting firm. The decision of the accounting
firm with respect to all disputed matters relating to the Trailing Twelve-Month Adjusted EBITDA shall be deemed final and conclusive and
shall be binding upon the Sellers and the Buyer. In addition, if the Sellers do not object to within the 20-day period referred to above,
the Trailing Twelve-Month Adjusted EBITDA shall be deemed final and conclusive and binding upon the Sellers and the Buyer. Notwithstanding
the foregoing, in the event that the Trailing Twelve-Month Adjusted EBITDA is determined by the Independent Accounting Firm to be equal
to or less than $970,000 and Buyer is not willing to pay at least $3,880,000, then either party may terminate this Agreement immediately
and neither party shall have any further obligation to the other party except as otherwise provided for in this Agreement.

 

(iii)
The Sellers shall be entitled to have access to the books and records and other information relating to the Company that was used by Liggett
& Webb to prepare the Quality of Earnings Report, including the work papers prepared in connection with the preparation of the Quality
of Earnings Report and shall be entitled to discuss such books and records and work papers with the Buyer and those persons responsible
for the preparation thereof.

 

(b)
Working Capital Adjustment.

 

(i)
At the Closing, the Sellers shall deliver to the Buyer an unaudited, combined estimated balance sheet of the Company (the “Preliminary
Balance Sheet”) as of the Closing Date together with a certificate of the Sellers stating that the Preliminary Balance Sheet
was prepared in accordance with GAAP so as to present fairly in all material respects the financial condition of Company on a combined
basis as of such date.

 

(ii)
Ninety days (90) after the Closing Date, the Buyer shall cause its auditor to prepare and deliver to the Sellers an unaudited, combined
balance sheet of the Company as of the Closing Date (the “Closing Date Balance Sheet”) and all calculations, work papers
and supporting documents (the “Supporting Documentation”) as of the Closing Date. The Closing Date Balance Sheet shall
be prepared in accordance with GAAP in a manner consistent with the Preliminary Balance Sheet so as to present fairly in all material
respects the financial condition of the Company.

 

    6

     

    

 

(iii)
If the Closing Working Capital exceeds the Minimum Working Capital, then the Buyer shall promptly (and, in any event, within fifteen (15)
days) pay to the Sellers an amount in cash that is equal to the deficiency. If the Minimum Working Capital exceeds the Closing Working
Capital, then the Sellers shall promptly (and, in any event, within fifteen (15) days) pay to the Buyer an amount in cash that is equal
to the deficiency.

 

(c)
If there is a dispute regarding differences between the Preliminary Balance Sheet and the Closing Date Balance Sheet or as to the calculation
of working capital as shown thereon, then the parties shall employ the same dispute resolution procedures within the same time periods
used to resolve disputes relating to Trailing Twelve-Month Adjusted EBITDA as set forth in Section 2.2(a)(ii).

 

(d)
Adjustment for Outstanding Indebtedness. The Cash Portion shall be decreased by the amount of any outstanding indebtedness of the
Company for borrowed money existing as of the Closing Date and the deducted amount shall be utilized to pay off such outstanding indebtedness.

 

2.3
Closing. The consummation of the Acquisition (the “Closing”) will take place by the reciprocal delivery of closing
documents by electronic mail, regular mail, fax or any other means mutually agreed upon by the parties hereto on a date that is no later
than two (2) Business Days immediately following the day on which the last of the conditions to closing contained in Article VII
(other than any conditions that by their nature are to be satisfied at the Closing) is satisfied or waived in accordance with this Agreement
or at such other location or on such other date as the Buyer and the Company may mutually determine (the date on which the Closing actually
occurs is referred to as the “Closing Date”).

 

2.4
Transactions to be Effected at the Closing.

 

(a)
At the Closing, the Buyer will (i) pay to the Sellers the Cash Portion of the Purchase Price, adjusted in accordance with subsection 2.2(a)
and, by paying such sum to the Sellers by transfer of immediately available funds in accordance with instructions provided by the Sellers,
and (ii) deliver to the Sellers all other documents, instruments or certificates required to be delivered by the Buyer at or prior to
the Closing pursuant to this Agreement, including, without limitation, the Buyer Notes.

 

(b)
At the Closing, the Sellers will deliver to the Buyer (i) an assignment of the Securities in form satisfactory to the Buyer showing the
Buyer as the sole owner of the Securities, and (ii) all other documents, instruments or certificates required to be delivered by
the Sellers at or prior to the Closing pursuant to this Agreement.

 

    7

     

    

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF THE SELLER

 

Each of the Sellers and the
Company represents and warrants to the Buyer that each statement contained in this Article III is true and correct as of the date hereof,
except as set forth in the schedule to be delivered to the Buyer in accordance with Section 6.10 hereof (the “Company Disclosure
Schedule”). The Company Disclosure Schedule has been arranged for purposes of convenience
only, in sections corresponding to the Sections of this Article III and Article IV. Each section of the Company Disclosure Schedule will be deemed to incorporate
by reference all information disclosed in any other section of the Company Disclosure Schedule.

 

3.1
Authority and Enforceability. Each of the Sellers has the requisite legal capacity to execute and deliver this Agreement, to perform
his respective obligations hereunder and to consummate the Acquisition and the other transactions contemplated hereby. This Agreement
has been duly executed and delivered by the Sellers and, assuming the due authorization, execution and delivery by each other party hereto,
constitutes a legal, valid and binding obligation of the Sellers, enforceable against the Sellers in accordance with its terms, except
as limited by (a) bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar Laws relating to creditors’
rights generally and (b) general principles of equity, whether such enforceability is considered in a proceeding in equity or at Law.

 

3.2
Noncontravention.

 

(a) Neither the execution
and the delivery of this Agreement nor the consummation of the Acquisition or the other transactions contemplated by this Agreement
will, with or without the giving of notice or the lapse of time or both, (i) to the knowledge of the Sellers and assuming compliance
with the filing and notice requirements set forth in Section 3.2(b)(i), violate any Law applicable to the Sellers or (ii) violate
any Contract to which either Seller is a party, except to the extent that any such violation would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect.

 

(b)
The execution and delivery of this Agreement by the Sellers does not, and the performance of this Agreement by the Sellers will not, require
any consent, approval, authorization or Permit of, or filing with or notification to, any Governmental Entity, except for (i) the filings
set forth in Section 3.2(b) of the Company Disclosure Schedule or (ii) where the failure to take such action would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

3.3
The Securities.

 

(a) The Sellers collectively
hold of record and own beneficially all of the Securities, free and clear of all Liens, other than (a) Liens for current real or personal
property Taxes that are not yet due and payable or that may hereafter be paid without material penalty or that are being contested in
good faith, (b) statutory Liens of landlords and workers’, carriers’ and mechanics’ or other like Liens incurred in
the ordinary course of business or that are being contested in good faith, (c) Liens and encroachments which do not materially interfere
with the present or proposed use of the properties or assets they affect, (d) Liens that will be released prior to or as of the Closing,
(e) Liens arising under this Agreement, (f) Liens created by or through the Buyer, and (g) Liens set forth in Section 3.3(a) of the
Company Disclosure Schedule (the “Permitted Liens”).

 

(b)
Except as set forth in this Agreement, neither Seller is a party to any Contract obligating such Seller to vote or dispose of any Securities
of, or other equity or voting interests in, the Company.

 

    8

     

    

 

3.4
Brokers’ Fees. Except as set forth in Section 3.4 of the Company Disclosure Schedule, neither Seller has any Liability
to pay any fees or commissions to any broker, finder or agent with respect to this Agreement, the Acquisition or the transactions contemplated
by this Agreement.

 

3.5
Investment Representations. The Buyer Notes are being acquired by each of the Sellers for his respective accounts, for investment
purposes and not with a view to the sale or distribution of all or any part of the Buyer Notes, nor with any present intention to sell
or in any way distribute the same, as those terms are used in the Securities Act of 1933, as amended (the “Securities Act”),
and the rules and regulations promulgated thereunder. Each of the Sellers has sufficient knowledge and experience in financial matters
so as to be capable of evaluating the merits and risks of purchasing the Buyer Notes. Each of the Sellers has reviewed copies of such
documents and other information as such Seller has deemed necessary in order to make an informed investment decision with respect to its
acquisition of the Buyer Notes. Each of the Sellers understands that the Buyer Notes may not be sold, transferred or otherwise disposed
of without registration under the Securities Act or the availability of an exemption therefrom, and that in the absence of an effective
registration statement covering the Buyer Notes or an available exemption from registration under the Securities Act, the Buyer Notes
must be held indefinitely. Further, each of the Sellers understands and has the financial capability of assuming the economic risk of
an investment in the Buyer Notes for an indefinite period of time. Each of the Sellers has been advised by the Buyer that the Sellers
will not be able to dispose of the Buyer Notes, or any interest therein, without first complying with the relevant provisions of the Securities
Act and any applicable state securities laws. Each of the Sellers understands that the provisions of Rule 144 promulgated under the Securities
Act, permitting the routine sales of the securities of certain issuers subject to the terms and conditions thereof, are not currently,
and may not hereafter be, available with respect to the Buyer Notes. Each of the Sellers acknowledges that the Buyer is under no obligation
to register the Buyer Notes except as otherwise expressly set forth in this Agreement or to furnish any information or take any other
action to assist the undersigned in complying with the terms and conditions of any exemption which might be available under the Securities
Act or any state securities laws with respect to sales of the Buyer Notes in the future. Each of the Sellers is an “Accredited Investor”
as defined in rule 501 (a) of Regulation D of the Act.

 

3.6
No Other Representations and Warranties. NO SELLER NOR ANY OTHER PERSON ON BEHALF OF ANY SELLER HAS MADE, OR SHALL BE DEEMED TO
HAVE MADE, AND NO SELLER NOR ANY OF ITS AGENTS OR REPRESENTATIVES IS LIABLE FOR OR BOUND IN ANY MANNER BY, ANY EXPRESS OR IMPLIED REPRESENTATIONS,
WARRANTIES, GUARANTIES, PROMISES OR STATEMENTS PERTAINING TO THE COMPANY, SELLERS OR THE SECURITIES, EXCEPT AS SPECIFICALLY SET FORTH
IN THIS AGREEMENT.

 

    9

     

    

 

ARTICLE
IV

REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANY

 

Each of the Sellers and
the Company represents and warrants to the Buyer that each statement contained in this Article IV is true and correct as of the date
hereof, except as set forth in the Company Disclosure Schedule. Any representation or warranty concerning the Company shall be
deemed to be a representation concerning the Company and its Subsidiaries, if any, as a whole unless the context specifically
requires otherwise.

 

4.1
Organization, Qualification and Corporate Power; Authority and Enforceability.

 

(a)
The Company is a corporation, duly organized, validly existing and in good standing under the Laws of the State of Florida, and has all
requisite corporate power and authority, directly or indirectly, to own, lease and operate its properties and assets and to carry on its
business as it is now being conducted. The Company is duly qualified or licensed as a foreign corporation to do business, and is in good
standing, in each jurisdiction where the character of its properties or assets owned, leased or operated by it or the nature of its activities
makes such qualification or licensing necessary, except where the failure to be so qualified or licensed would not be reasonably expected
to have, individually or in the aggregate, a Material Adverse Effect.

 

(b)
The Company has the requisite corporate power and authority to execute and deliver this Agreement, to perform its obligations hereunder
and to consummate the transactions contemplated hereby. The execution, delivery and performance by the Company of this Agreement and the
consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the
Company, and no other action is necessary on the part of the Company to authorize this Agreement or to consummate the Acquisition or the
other transactions contemplated hereby. This Agreement has been duly executed and delivered by the Company and, assuming the due authorization,
execution and delivery by each other party hereto, constitutes a legal, valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms, except as limited by (a) bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance
or other similar Laws relating to creditors’ rights generally and (b) general principles of equity, including principals of commercial
reasonableness , good faith and fair dealing, whether such enforceability is considered in a proceeding in equity or at Law.

 

4.2
Subsidiaries. The Company has no Subsidiaries.

 

4.3
Capitalization.

 

(a)
The authorized and outstanding capital stock of the Company is as set forth in Section 4.3(a) of the Company Disclosure Schedule.
No other capital stock of the Company is authorized, issued or outstanding.

 

(b)
There are no outstanding options, warrants or other securities or subscription, preemptive or other rights convertible into or exchangeable
or exercisable for any shares of capital stock or other equity or voting interests of the Company and there are no “phantom equity”
rights, interest appreciation rights or other similar rights with respect to the Company. There are no Contracts of any kind to which
the Company is a party or by which the Company is bound, obligating the Company to issue, deliver, grant or sell, or cause to be issued,
delivered, granted or sold, additional equity interests of, or voting interests in, or options, warrants or other securities or subscription,
preemptive or other rights convertible into, or exchangeable or exercisable for, equity interests of, or other voting interests in, the
Company, or any “phantom equity” right, equity appreciation right or other similar right with respect to the Company, or obligating
the Company to enter into any such Contract.

 

    10

     

    

 

(c)
There are no securities or other instruments or obligations of the Company, the value of which is in any way based upon or derived from
any capital or voting stock of the Company or having the right to vote (or convertible into, or exchangeable or exercisable for, securities
having the right to vote) on any matters on which the Company’s stockholders may vote.

 

(d)
There are no Contracts, contingent or otherwise, obligating the Company to repurchase, redeem or otherwise acquire any securities of,
or other equity or voting interests in, the Company. There are no voting trusts, registration rights agreements or stockholder agreements
to which the Company is a party with respect to the voting of the capital stock of the Company, as applicable, or with respect to the
granting of registration rights for any of the capital stock of the Company. There are no rights plans affecting the Company.

 

(e)
Except as set forth in Section 4.3(e) of the Company Disclosure Schedule, there are no bonds, debentures, notes or other indebtedness
of the Company.

 

4.4
Noncontravention.

 

(a) Neither the execution
and delivery of this Agreement nor the consummation of the Acquisition and the other transactions contemplated by this Agreement
will, with or without the giving of notice or the lapse of time or both, (i) violate any provision of the articles of incorporation
or bylaws (or comparable organization documents, as applicable) of the Company, (ii) to the Knowledge of the Sellers and assuming
compliance with the filing and notice requirements set forth in Section 4.4(b) (i), violate any Law applicable to the Company on the
date hereof or (iii) except as set forth in Section 4.4(a) of the Company Disclosure Schedule, violate any Contract to which
the Company is a party, except with respect to those third party consents that the Sellers shall use reasonable efforts to obtain
pursuant to Section 6.1 and in the case of clauses (ii) and (iii) to the extent that any such violation would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect.

 

(b)
The execution and delivery of this Agreement by the Company does not, and the performance of this Agreement by the Company will not, require
any consent, approval, authorization or Permit of, or filing with or notification to, any Governmental Entity, except for (i) the filings
set forth in Section 4.4(b) of the Company Disclosure Schedule or (ii) where the failure to take such action would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

4.5
Financial Statements. Section 4.5 of the Company Disclosure Schedule contains true and complete copies of (i) the unaudited
balance sheet of the Company for the two years ended December 31, 2020 and December 31, 2019, and for the six months ended June 30, 2021;
and (ii) the related unaudited statements of income and cash flows for the two years ended December 31, 2020 and December 31, 2019, and
for the six months ended June 30, 2021 (the “Financial Statements”). The Financial Statements have been prepared in
accordance with GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto) and,
on that basis, fairly present, in all material respects, the financial condition, results of operations and cash flows of the Company
as of the indicated dates and for the indicated periods.

 

    11

     

    

 

4.6
Taxes.

 

(a)
All material Tax Returns required to have been filed by the Company have been filed, and each such Tax Return reflects the liability for Taxes in all material respects. All Taxes
shown on such Tax Returns as due have been paid or accrued.

 

(b)
To the Knowledge of the Sellers, there is no audit pending against the Company in respect of any Taxes. There are no Liens on any of the
assets of the Company that arose in connection with any failure (or alleged failure) to pay any Tax, other than Liens for Taxes not yet
due and payable.

 

(c)
The Company has withheld and paid or accrued for all material Taxes required to have been withheld and paid or accrued for in connection
with amounts paid or owing to any third party.

 

(d)
The Company has not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment
or deficiency.

 

(e)
The Company is not a party to any Tax allocation or sharing agreement.

 

4.7
Compliance with Laws and Orders; Permits.

 

(a)
The Company is in compliance with all Laws and Orders to which the business of the Company is subject, except where such failure to comply
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

(b)
The Company owns, holds, possesses or lawfully uses in the operation of its business all Permits that are necessary for it to conduct
its business as now conducted, except where such failure to own, hold, possess or lawfully use such Permit would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect.

 

4.8
No Undisclosed Liabilities. The Company does not have any Liability, of a nature that would be required to be disclosed on a corporate
balance sheet prepared in accordance with GAAP, except for (i) liabilities which have arisen since the date of the Financial Statements
in the ordinary course of business (none of which results from, arises out of, relates to, is in the nature of, or was caused by any breach
of contract, breach of warranty, tort, infringement, or violation of law); or (ii) liabilities that are adequately reserved against.

 

4.9
Tangible Personal Assets.

 

(a)
The Company has good title to, or a valid interest in, all of their tangible personal assets, free and clear of all Liens, other than
(i) Permitted Liens or (ii) Liens that, individually or in the aggregate, do not materially interfere with the ability of the Company
thereof to conduct its business as currently conducted and do not adversely affect the value of, or the ability to sell, such personal
properties and assets.

 

    12

     

    

 

(b)
The Company’s tangible personal assets are in good operating condition, working order and repair, subject to ordinary wear and tear,
free from defects (other than defects that do not interfere with the continued use thereof in the conduct of normal operations) and are
suitable for the purposes for which they are currently being used.

 

4.10
Real Property.

 

(a)
Owned Real Property. The Company does not own any real property.

 

(b)
Leased Real Property. Section 4.10(b) of the Company Disclosure Schedule contains a list of all leases and subleases (collectively,
the “Real Property Leases”) under which the Company is either lessor or lessee (the “Real Property”).
The Sellers have heretofore made available to the Buyer true and complete copies of each Real Property Lease. To the Knowledge of the
Sellers, (i) all Real Property Leases are valid and binding Contracts of the Company and are in full force and effect (except for those
that have terminated or will terminate by their own terms), and (ii) neither the Company nor any other party thereto, is in violation
or breach of or default (or with notice or lapse of time, or both, would be in violation or breach of or default) under the terms of any
such Contract, in each case, except where such default would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.

 

4.11
Intellectual Property.

 

(a)
“Intellectual Property” means (i) trade secrets, inventions, confidential and proprietary information, know-how, formulae
and processes, (ii) patents (including all provisionals, reissues, divisions, continuations and extensions thereof) and patent applications,
(iii) trademarks, trade names, trade dress, brand names, domain names, trademark registrations, trademark applications, service marks,
service mark registrations and service mark applications (whether registered, unregistered or existing at common law, including all goodwill
attaching thereto), (iv) copyrights, including copyright registrations, copyright applications and unregistered common law copyrights;
(v) and all licenses for the Intellectual Property listed in items (i) – (iv) above.

 

(b)
Section 4.11(b) of the Company Disclosure Schedule sets forth a list that includes all material Intellectual Property owned by
the Company (the “Company-Owned Intellectual Property”) that is registered or subject to an application for registration
(including the jurisdictions where such Company-Owned Intellectual Property is registered or where applications have been filed, and all
registration or application numbers, as appropriate).

 

(c)
All necessary registration, maintenance and renewal fees have been paid and all necessary documents have been filed with the United States
Patent and Trademark Office or foreign patent and trademark office in the relevant foreign jurisdiction for the purposes of maintaining
the registered Company-Owned Intellectual Property.

 

    13

     

    

 

(d)
Except as set forth on Section 4.11(d) of the Company Disclosure Schedule, (i) the Company is the exclusive owner of the Company-Owned
Intellectual Property free and clear of all Liens (other than Permitted Liens); (ii) to the Knowledge of the Sellers no proceedings have
been instituted, are pending or are threatened that challenge the rights of the Company in or the validity or enforceability of the Company-Owned
Intellectual Property; (iii) to the Knowledge of the Sellers, neither the use of the Company-Owned Intellectual Property as currently
used by the Company in the conduct of the Company’s business, nor the conduct of the business as presently conducted by the Company
infringes, dilutes, misappropriates or otherwise violates in any material respect the Intellectual Property rights of any Person; and
(iv) as of the date of this Agreement, the Company has made no claim of a violation, infringement, misuse or misappropriation by any Person,
of its rights to, or in connection with, the Company-Owned Intellectual Property.

 

(e)
Except as set forth in Section 4.11(e) of the Company Disclosure Schedule, the Company has not permitted or licensed any Person
to use any Company-Owned Intellectual Property.

 

(f)
Section 4.11(f) of the Company Disclosure Schedule sets forth a complete and accurate list of all licenses, other than “off
the shelf” commercially available software programs, pursuant to which the Company licenses from a Person Intellectual Property
that is material to and used in the conduct of the business by the Company.

 

(g) To the Knowledge of
the Sellers, the Company is not in default in the performance, observance or fulfillment of any obligation, covenant or condition
contained in any Contract pursuant to which any third party is authorized to use any Company-Owned Intellectual Property or pursuant
to which the Company is licensed to use Intellectual Property owned by a third party, except where such default would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

4.12
Absence of Certain Changes or Events. Since the date of the Financial Statements, no event has occurred that has had, individually
or in the aggregate, a Material Adverse Effect. Without limiting the generality of the foregoing, since that date:

 

(a)
the Company has not sold, leased, transferred, or assigned any of its assets, tangible or intangible, other than for a fair consideration
in the ordinary course of business;

 

(b)
the Company has not entered into any agreement, contract, lease, or license (or series of related agreements, contracts, leases, and licenses)
outside the ordinary course of business;

 

(c) no party (including
the Company) has accelerated, terminated, modified, or cancelled any agreement, contract, lease, or license (or series of related
agreements, contracts, leases, and licenses) involving more than $50,000 to which the Company is a party or by which it is
bound;

 

(d)
the Company has not imposed any Liens upon any of its assets, tangible or intangible;

 

(e) the Company has not
made any capital expenditure (or series of related capital expenditures) either involving more than $50,000 or outside the ordinary
course of business;

 

(f) the Company has not
made any capital investment in, any loan to, or any acquisition of the securities or assets of, any other Person (or series of
related capital investments, loans, and acquisitions) either involving more than $50,000 or outside the ordinary course of
business;

 

    14

     

    

 

(g)
the Company has not transferred, assigned, or granted any license or sublicense of any rights under or with respect to any Intellectual
Property;

 

(h)
there has been no change made or authorized in the articles of incorporation, or bylaws of the Company;

 

(i)
the Company has not issued, sold, or otherwise disposed of any of its capital stock, or granted any options, warrants, or other rights
to purchase or obtain (including upon conversion, exchange, or exercise) any of its capital stock;

 

(j)
the Company has not made any loan to, or entered into any other transaction with, any of its directors, officers, and employees outside
the ordinary course of business;

 

(k)
the Company has not entered into any employment contract or modified the terms of any existing such contract or agreement;

 

(l)
the Company has not granted any increase in the base compensation of any of its directors, officers, and employees outside the ordinary
course of business;

 

(m)
the Company has not committed to any of the foregoing.

 

4.13
Contracts.

 

(a)
Except as set forth in Section 4.13(a) of the Company Disclosure Schedule, as of the date hereof, the Company is not a party to
or bound by any: (i) Contract not contemplated by this Agreement that materially limits the ability of the Company to engage or compete
in any manner of the business presently conducted by the Company; (ii) Contract that creates a partnership or joint venture or similar
arrangement with respect to any material business of the Company; (iii) indenture, credit agreement, loan agreement, security agreement,
guarantee, note, mortgage or other evidence of indebtedness or agreement providing for indebtedness in excess of $50,000; (iv) Contract
that relates to the acquisition or disposition of any material business (whether by merger, sale of stock or other equity interests, sale
of assets or otherwise) other than this Agreement; and (v) Contract that involves performance of services or delivery of goods or materials
by or to the Company in an amount or with a value in excess of $50,000 in any 12-month period (which period may extend past the Closing).

 

(b)
The Sellers have heretofore made available to the Buyer true and complete copies of each of the Contracts set forth in Section 4.13(a)
of the Company Disclosure Schedule. To the Knowledge of the Sellers, (i) all such Contracts are valid and binding, (ii) all such Contracts
are in full force and effect (except for those that have terminated or will terminate by their own terms), and (iii) neither the Company
nor any other party thereto, is in violation or breach of or default under (or with notice or lapse of time, or both, would be in violation
or breach of or default under) the terms of any such Contract, in each case, except where such default would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect.

 

    15

     

    

 

4.14
Litigation. Except as set forth in Section 4.14 of the Company Disclosure Schedule, there is no Action pending or, to the
Knowledge of the Sellers, threatened against the Company that (a) challenges or seeks to enjoin, alter or materially delay the Acquisition
or (b) would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

4.15
Employee Benefits.

 

(a)
Section 4.15(a) of the Company Disclosure Schedule includes a list of all Benefit Plans maintained or contributed to by the Company
(the “Company Benefit Plans”). The Sellers have delivered or made available to the Buyer copies of (i) each Company
Benefit Plan, (ii) the most recent summary plan description for each Company Benefit Plan for which such a summary plan description is
required and (iii) the most recent favorable determination letters from the IRS with respect to each Company Benefit Plan intended to
qualify under Section 401(a) of the Code.

 

(b)
Except as set forth in Section 4.15(b) of the Company Disclosure Schedule, (i) none of the Company Benefit Plans is subject to
Title IV of ERISA; (ii) each Company Benefit Plan that is intended to be qualified under Section 401(a) of the Code is subject to a favorable
determination letter from the IRS and, to the Knowledge of the Sellers, no event has occurred and no condition exists that is reasonably
likely to result in the revocation of any such determination; and (iii) each Company Benefit Plan is in compliance with all applicable
provisions of ERISA and the Code, except for instances of noncompliance that would not reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect.

 

4.16
Labor and Employment Matters. Section 4.16 of the Company Disclosure Schedule sets forth a list of all written employment
agreements that obligate the Company to pay an annual salary of $50,000 or more and to which the Company is a party. To the Knowledge
of the Sellers, there are no pending labor disputes, work stoppages, requests for representation, pickets, work slow-downs due to labor
disagreements or any actions or arbitrations that involve the labor or employment relations of the Company. The Company is not party to
any collective bargaining agreement.

 

4.17
Environmental. Except (i) as set forth in Section 4.17 of the Company Disclosure Schedule or (ii) for any matter that would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, to the Knowledge of the Sellers (a) the
Company is in compliance with all applicable Laws relating to protection of the environment (“Environmental Laws”),
(b) the Company possesses and is in compliance with all Permits required under any Environmental Law for the conduct of their operations
and (c) there are no Actions pending against the Company alleging a violation of any Environmental Law.

 

4.18
Insurance. Section 4.18 of the Company Disclosure Schedule sets forth a list of each insurance policy that covers the Company
or its businesses, properties, assets, directors, officers or employees (the “Policies”). Such Policies are in full
force and effect in all material respects and the Company is not in violation or breach of or default under any of their obligations under
any such Policy, except where such default would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect.

 

    16

     

    

 

4.19
Brokers’ Fees. Except as set forth in Section 4.19 of the Company Disclosure Schedule, which such fees shall be paid
prior to or at Closing with the Sellers’ cash, the Sellers and the Company have no Liability to pay any fees or commissions to any
broker, finder or agent with respect to this Agreement, the Acquisition or the transactions contemplated by this Agreement.

 

4.20
Certain Business Relationships with the Company. Except as set forth in Section 4.20 of the Company Disclosure Schedule,
neither the Sellers, nor any Affiliate of the Sellers, have been involved in any business arrangement or relationship with the Company
within the past 12 months, and neither the Sellers, nor any Affiliate of the Sellers, own any asset, tangible or intangible, which is
used in the Business.

 

4.21
Equipment. Section 4.21 of the Company Disclosure Schedule sets forth a complete and accurate list of all plants, fixtures,
machinery, installations, equipment, furniture, tools, spare parts, supplies, materials and other personal property (collectively, the
“Equipment”) owned by the Company other than items having a net book or market value individually of less than five
thousand dollars ($5,000) or expensed for tax purposes, as of the date of the Financial Statements. The Company has not acquired an item
of Equipment for in excess of such amount since such date. The Equipment, and all personal property held by the Company, are utilized
by the Company in the ordinary course of business.

 

4.22
Customers and Suppliers. Section 4.22 of the Company Disclosure Schedule sets forth a correct and complete list of the top
20 customers and top 20 suppliers of the Company during the fiscal year ended December 31, 2020 and indicates with respect to each the
name, address and dollar volume of business with the Company (including the primary categories, based on purchases or sales, of products
or services bought or sold). The Company is not required to provide any material bonding or other financial security arrangements in connection
with its transactions with any customer or supplier required to be disclosed on Section 4.22 of the Company Disclosure Schedule
except as set forth therein. Since the date of the Financial Statements, no customer or supplier required to be disclosed on Section
4.22 of the Company Disclosure Schedule has terminated its relationship with, or materially reduced its purchases from or sales to,
the Company.

 

4.23 Potential
Conflicts of Interest. Except as set forth in Section 4.23 of the Company Disclosure Schedule, no officer, director,
manager, member, stockholder (or Affiliate thereof) or, to the Knowledge of the Sellers, employee of the Company (a) owns, directly
or indirectly, any interest in (excepting not more than 1% stock or other equity securities for investment purposes in securities of
publicly held and traded companies) or is an officer, director, manager, employee or consultant of any Person which is a competitor,
lessor, lessee, customer or supplier of Company, unless such interest is owned on the date hereof and such Person is not within a
ten (10) mile radius of any of the manufacturing operations currently being operated by the Company; (b) owns, directly or
indirectly, in whole or in part, any tangible or intangible property which the Company is using or the use of which is necessary for
their business; (b) has any cause of action or other claim whatsoever against, or owes any amount to, any of the Company, except for
claims in the ordinary course of business, such as for accrued vacation pay, accrued benefits under any Company Benefit Plan and
similar matters and agreements; or (c) is party to any agreement, contract or commitment with any of the Company or has received any
loan, advance or investment from the Company that has not been repaid in full prior to the date hereof.

 

    17

     

    

 

4.24   Bank
Accounts. Section 4.24 of the Company Disclosure Schedule sets forth a correct and complete list of: (i) each of the bank accounts
of the Company, together with a true and complete list of the authorized signatories for such accounts; and (ii) the names of all Persons
authorized to borrow money or sign notes on behalf of the Company.

 

4.25
Accounts Receivable. Except as set forth in Section 4.25 of the Company Disclosure Schedule, all accounts and notes receivable
of the business of the Company arose in the ordinary and usual course of the business, represent valid obligations due, and except for
installment loan contracts and customer side notes either have been collected in full or, to the Knowledge of the Sellers, will be collected
in full not later than 60 days after the invoice or due date of such receivables.

 

4.26
Disclosure. The representations and warranties contained in this Article IV do not contain any untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements and information contained in this Article IV not misleading.

 

4.27
No Other Representations and Warranties. NONE OF THE COMPANY, OR ANY OTHER PERSON ON BEHALF OF THE COMPANY HAS MADE, OR SHALL BE
DEEMED TO HAVE MADE, AND NEITHER THE COMPANY NOR OR ANY OF ITS DIRECTORS, MANAGERS, OFFICERS, EMPLOYEES, AGENTS OR REPRESENTATIVES IS
LIABLE FOR OR BOUND IN ANY MANNER BY, ANY EXPRESS OR IMPLIED REPRESENTATIONS, WARRANTIES, GUARANTIES, PROMISES OR STATEMENTS PERTAINING
TO THE COMPANY, OR THE COMPANY EQUITY, EXCEPT AS SPECIFICALLY SET FORTH IN THIS AGREEMENT.

 

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF THE BUYER

 

The Buyer represents and warrants
to the Sellers that each statement contained in this Article V is true and correct as of the date hereof. Any representation or warranty concerning the Buyer shall be deemed
to be a representation concerning the Buyer and its Subsidiaries, if any, as a whole unless the context
specifically requires otherwise.

 

5.1
Organization. The Buyer is a corporation, duly organized, validly existing and in good standing under the laws of the state of
Delaware.

 

5.2
Authorization. The Buyer has the requisite power and authority to execute and deliver this Agreement, to perform its obligations
hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance by the Buyer of this Agreement,
and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary action, and no other action on
the part of the Buyer is necessary to authorize this Agreement or to consummate the transactions contemplated hereby (other than compliance
with the filing and notice requirements set forth in Section 5.3(b)(i)). This Agreement has been duly executed and delivered by the Buyer
and, assuming the due authorization, execution and delivery by each of the other parties hereto, constitutes a legal, valid and binding
obligation of the Buyer enforceable against the Buyer in accordance with its terms, except as limited by (a) bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or other similar Laws relating to creditors’ rights generally and (b) general principles of equity,
whether such enforceability is considered in a proceeding in equity or at Law.

 

    18

     

    

 

5.3
Noncontravention.

 

(a)
Neither the execution and the delivery of this Agreement, nor the consummation of the Acquisition and the other transactions contemplated
by this Agreement, will, with or without the giving of notice or the lapse of time or both, (i) violate any provision of the certificate
of incorporation or bylaws (or comparable organization documents, as applicable) of the Buyer, (ii) violate any Law applicable to
the Buyer on the date hereof or (iii) violate any Contract to which the Buyer is a party, except in the case of clauses (ii) and
(iii) to the extent that any such violation would not reasonably be expected to prevent or materially delay the consummation of the Acquisition
and the other transactions contemplated by this Agreement.

 

(b)
The execution and delivery of this Agreement by the Buyer does not, and the performance of this Agreement by the Buyer will not, require
any consent, approval, authorization or Permit of, or filing with or notification to, any Governmental Entity, except for (i) the filings
set forth in Section 3.2(b)(i) or (ii) where the failure to take such action would not reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect.

 

5.4
Litigation. There are no Legal Proceedings pending or, to the knowledge of the Buyer threatened against the Buyer that, if adversely
determined, are reasonably likely to prohibit or restrain the ability of the Buyer to enter into this Agreement or consummate the Transaction
and the other transactions contemplated by this Agreement.

 

5.5
Brokers’ Fees. The Buyer has no Liability to pay any fees or commissions to any broker, finder or agent with respect to this
Agreement, the Acquisition or the transactions contemplated by this Agreement that could result in any Liability being imposed on the
Sellers or the Company.

 

5.6
Inspection; Non-Reliance. Buyer is an informed and sophisticated purchaser, and has engaged expert advisors, experienced in the
evaluation and purchase of businesses such as its acquisition of the Securities as contemplated by this Agreement. Seller has given Buyer
reasonable access to the employees, documents and facilities of the Company, and Buyer has undertaken such investigation and has been
provided with and has evaluated such documents and information as it has deemed necessary to enable it to make an informed and intelligent
decision with respect to the execution, delivery and performance of this Agreement.

 

BUYER ACKNOWLEDGES THAT (A) NONE OF
THE COMPANY, ANY SELLER, OR ANY PERSON ON BEHALF OF THE COMPANY OR SELLERS IS MAKING ANY REPRESENTATIONS OR WARRANTIES WHATSOEVER, EXPRESS
OR IMPLIED, BEYOND THOSE EXPRESSLY MADE BY SELLERS IN ARTICLE III OR BY THE COMPANY IN ARTICLE IV, AND (B) BUYER HAS NOT BEEN INDUCED
BY, OR RELIED UPON, ANY REPRESENTATIONS, WARRANTIES, OR STATEMENTS (WRITTEN OR ORAL), WHETHER EXPRESS OR IMPLIED, MADE BY ANY PERSON THAT
ARE NOT EXPRESSLY SET FORTH IN THIS AGREEMENT. BUYER AGREES TO ACCEPT THE SECURITIES ON THE CLOSING DATE BASED UPON ITS OWN INSPECTION,
EXAMINATION AND DETERMINATION WITH RESPECT THERETO AS TO ALL MATTERS AND WITHOUT RELIANCE UPON ANY EXPRESSED OR IMPLIED REPRESENTATIONS
OR WARRANTIES OF ANY NATURE MADE BY SELLER OR THE COMPANY OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICER, EMPLOYEES, STOCKHOLDERS, PARTNERS,
MEMBERS, ADVISORS, OR OTHER REPRESENTATIVES, EXCEPT AS SPECIFICALLY AND EXPRESSLY SET FORTH IN THIS AGREEMENT. WITHOUT LIMITING THE GENERALITY
OF THE FOREGOING, BUYER SPECIFICALLY ACKNOWLEDGES THAT NO REPRESENTATIONS OR WARRANTIES ARE MADE WITH RESPECT TO ANY PROJECTIONS, FORECASTS,
ESTIMATES, BUDGETS OR PROSPECTIVE INFORMATION THAT MAY HAVE BEEN MADE AVAILABLE TO BUYER, ITS AFFILIATES OR ANY OF THEIR REPRESENTATIVES,
EXCEPT THOSE, IF ANY, EXPRESSLY MADE BY SELLERS OR THE COMPANY IN THIS AGREEMENT.

 

    19

     

    

 

ARTICLE VI

COVENANTS

 

6.1
Consents. The Sellers and the Company will use their commercially reasonable efforts to obtain any required third-party consents
to the Acquisition and the other transactions contemplated by this Agreement in writing from each Person.

 

6.2
Operation of the Company’s Business. During the period commencing on the date hereof and ending at the earlier of the Closing
and the termination of this Agreement in accordance with Article VIII, the Company, except (i) as otherwise contemplated by this Agreement,
(ii) as required by applicable Law or (iii) with the prior written consent of the Buyer (which consent will not be unreasonably withheld
or delayed), will use commercially reasonable efforts to carry on their business in a manner consistent with past practice and not take
any action or enter into any transaction that would result in the following:

 

(a)
any change in the articles of incorporation or bylaws of the Company or any amendment of any material term of any outstanding security
of the Company;

 

(b)
any issuance or sale of any additional shares of, or rights of any kind to acquire any capital stock of any class of the Company (whether
through the issuance or granting of options or otherwise);

 

(c)
any incurrence, guarantee or assumption by the Company of any indebtedness for borrowed money other than in the ordinary course of business
in amounts and on terms consistent with past practice;

 

(d) any change in any
method of accounting, accounting principle or accounting practice by the Company which would reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect;

 

    20

     

    

 

(e)
except in the ordinary course of business (i) any adoption or material amendment of any of the Company Benefit Plans, (ii) any entry into
any collective bargaining agreement with any labor organization or union, (iii) any entry into an employment agreement or (iv) any increase
in the rate of compensation to any employee in an amount that exceeds 10% of such employee’s current compensation; provided,
that the Company may (A) take any such action for employees in the ordinary course of business or pursuant to any existing Contracts or
Company Benefit Plans and (B) adopt or amend any of the Company Benefit Plans if the cost to such Person of providing benefits thereunder
is not materially increased;

 

(f)
except in the ordinary course of business, any cancellation, modification, termination or grant of waiver of any material Permits or Contracts
to which the Company is a party, which cancellation, modification, termination or grant of waiver would, individually or in the aggregate,
have a Material Adverse Effect;

 

(g)
any change in the Tax elections made by the Company or in any accounting method used by the Company for Tax purposes, where such Tax election
or change in accounting method may have a material effect upon the Tax Liability of the Company for any period or set of periods, or the
settlement or compromise of any material income Tax Liability of the Company;

 

(h)
except in the ordinary course of business, any acquisition or disposition of any business or any material property or asset (including,
without limitation, any of the Company’s Intellectual Property) of the Company (whether by merger, consolidation or otherwise) by
the Company;

 

(i)
any grant of a Lien on any properties and assets of the Company that would have, individually or in the aggregate, a Material Adverse
Effect; or

 

(j)
any entry into any agreement or commitment to do any of the foregoing.

 

6.3
Access. The Company will permit the Buyer and its Representatives to have reasonable access at all reasonable times, and in a manner
so as not to interfere with the normal business operations of the Company, to the premises, properties, personnel, books, records (including
Tax records), Contracts and documents of or pertaining to the Company.

 

6.4
Notice of Developments. The Sellers and the Company will give prompt written notice to the Buyer of any event that would reasonably
be expected to give rise to, individually or in the aggregate, a Material Adverse Effect or would reasonably be expected to cause a breach
of any of their respective representations, warranties, covenants or other agreements contained herein. The Buyer will give prompt written
notice to the Sellers and the Company of any event that could reasonably be expected to cause a breach of any of its representations,
warranties, covenants or other agreements contained herein or could reasonably be expected to, individually or in the aggregate, prevent
or materially delay the consummation of the Acquisition and the other transactions contemplated by this Agreement. The delivery of any
notice pursuant to this Section 6.4 will not limit, expand or otherwise affect the remedies available hereunder (if any) to the party
receiving such notice.

 

    21

     

    

 

6.5
No Solicitation.

 

(a)
The Sellers and the Company will, and will cause each of their Representatives to, cease immediately any existing discussions regarding
a Transaction Proposal.

 

(b)
From and after the date of this Agreement, without the prior consent of the Buyer, neither the Sellers nor the Company will, nor will
they authorize or permit any of their respective Representatives to, directly or indirectly through another Person to, (i) solicit,
initiate or encourage (including by way of furnishing information), or take any other action designed to facilitate any inquiries, proposals
or offers from any Person that constitute, or would reasonably be expected to constitute, a Transaction Proposal, (ii) participate
in any discussions or negotiations (including by way of furnishing information) regarding any Transaction Proposal or (iii) otherwise
cooperate in any way with, or assist or participate in, facilitate or encourage, any effort or attempt by any other Person to do or seek
any of the foregoing.

 

(c)
In addition, the Sellers shall immediately communicate to the Buyer the terms of any Transaction Proposal received by the Sellers or the
Company, or any of their Representatives.

 

6.6
Taking of Necessary Action; Further Action. Subject to the terms and conditions of this Agreement, each of the Sellers, the Company
and the Buyer will take all such reasonable and lawful action as may be necessary or appropriate in order to effectuate the Acquisition
in accordance with this Agreement as promptly as practicable.

 

6.7
Covenant not to Compete. For a period of three years from and after the Closing (the “Noncompetition Period”),
the Sellers shall not engage directly or indirectly in any business that is competitive with the current business of the Company (the
“Business”) in any geographic area in which the Business is conducted as of the Closing Date; provided, however, that
no owner of less than 1% of the outstanding stock of any publicly-traded corporation shall be deemed to engage solely by reason thereof
in any of its businesses. During the Noncompetition Period, the Sellers shall not induce or attempt to induce any customer, or supplier
of the Buyer or any affiliate of the Buyer to terminate its relationship with the Buyer or any Affiliate of the Buyer or to enter into
any business relationship to provide or purchase the same or substantially the same services as are provided to or purchased from the
Business which might harm the Buyer or any Affiliate of the Buyer. During the Noncompetition Period, the Sellers shall not, on behalf
of any entity other than the Buyer or an Affiliate of the Buyer, hire or retain, or attempt to hire or retain, in any capacity any Person
who is, or was at any time during the preceding twelve (12) months, an employee or officer of the Company. If the final judgment of a
court of competent jurisdiction declares that any term or provision of this Section 6.7 is invalid or unenforceable, the parties agree
that the court making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration, or area
of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term
or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or
provision, and this Agreement shall be enforceable as so modified after the expiration of the time within which the judgment may be appealed.

 

    22

     

    

 

6.8
Financial Information. The Sellers shall cooperate with the Buyer and the Buyer’s independent certified public accounting
firm in order to enable the Buyer to create audited financial statements prepared in accordance with the GAAP for the two full fiscal
years preceding the Closing Date, by making available the Seller’s records as they are maintained in the ordinary course of business
and answering reasonable questions.

 

6.9
Transfer of Cash and Cash Equivalents. On or prior to the Closing, the Company and Sellers will transfer, or cause to be distributed
all cash and cash equivalents of the Company to, among other things, pay any fees owed by Company to brokers or advisors (including termination
fees under any advisory agreement) and any indebtedness for borrowed money.

 

6.10
Company Disclosure Schedule. The Parties acknowledge and agree that (i) the Sellers and the Company have not yet delivered a definitive
Company Disclosure Schedule to this Agreement to the Buyer, and (ii) the Buyer has not been provided with copies of, nor had an opportunity
to review, the items to be referred to on the Company Disclosure Schedule. The Sellers shall deliver (and shall cause the Company to deliver)
to the Buyer all of the schedules, including a definitive Company Disclosure Schedule to the Agreement, and documents
referred to thereon, in final form as soon as reasonably practicable after the date hereof.  The Buyer shall have 20 days following
delivery of such Company Disclosure Schedule and such documents in which to terminate this Agreement if the Buyer objects to any
information contained in such Company Disclosure Schedule or the contents of any such document and Buyer and Sellers cannot
agree on mutually satisfactory modifications thereto or to this Agreement.

 

6.11
Piggyback Registration Rights. If the Buyer files a registration statement with the Commission covering the sale of shares of its
Common Stock (other than a registration statement on Form S-4 or S-8, or on another form, or in another context, in which such “piggyback”
registration would be inappropriate such as the Buyer’s initial public offering of its securities), then, for a period commencing
on the date of this Agreement and terminating on the second (2nd) anniversary of the date hereof, the Buyer shall give written
notice of such proposed filing to the Sellers as soon as practicable but in no event less than ten (10) business days before the anticipated
filing date, which notice shall describe the amount and type of securities to be included in such offering, the intended method(s) of
distribution, and the name of the proposed managing underwriter or underwriters, if any, of the offering, and offer to the Sellers in
such notice the opportunity to register the sale of such number of shares common stock underlying the Buyer Notes (the “Underlying
Shares”) as the Sellers may request in writing within five (5) business days after receipt of such notice (a “Piggyback
Registration”). The Buyer shall cause such Underlying Shares to be included in such registration and shall use its best efforts
to cause the managing underwriter or underwriters of a proposed underwritten offering to permit the Underlying Shares requested to be
included in a Piggyback Registration on the same terms and conditions as any similar securities of the Buyer and to permit the sale or
other disposition of such Underlying Shares in accordance with the intended method(s) of distribution thereof. The Sellers agree that
if the Sellers propose to include the Underlying Shares or any portion of them in Piggyback Registration that involves an underwriter
or underwriters, the Sellers shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected
for such Piggyback Registration. This provision shall expire once the Underlying Shares may be freely sold by the Sellers under Rule 144
promulgated under the Securities Act without restriction as to the volume of Underlying Shares that may be sold.

 

    23

     

    

 

6.12
Tag Along Right. The Buyer shall not permit the Buyer’s Executive Chairman (Alfonso J. Cervantes) or its President (Darren
Minton) (each, a “Tag Along Seller”) to sell any shares of common stock, other capital stock or other securities of
the Buyer held by them to a third party (other than to an Affiliate or family member) without the consent of the Sellers unless the Sellers
are able to sell the Sellers’ Underlying Shares to such third party on a pro rata basis. For purposes of this provision, “pro
rata basis” means the number of total Underlying Shares then held by the Sellers multiplied by a fraction where the numerator
is the number of shares of Common Stock of the Buyer on a fully-diluted basis that is owned by the Tag Along Seller who is then selling
securities and the denominator is the total number of shares of Common Stock of the Buyer that are outstanding on a fully-diluted basis.
The Buyer shall treat as void any attempt by the Tag Along Seller to make a transfer of securities of the Buyer in violation of this provision
and shall not register any such transfer on the books and records of the Buyer. This provision shall expire immediately following the
closing of the Buyer’s initial public offering of securities, including a public offering of securities under Regulation A of the
Securities Act.

 

ARTICLE VII

CONDITIONS TO OBLIGATIONS TO CLOSE

 

7.1
Conditions to Obligation of the Buyer. The obligation of the Buyer to consummate the Acquisition is subject to the satisfaction
or waiver by the Buyer of the following conditions:

 

(a)
The representations and warranties of the Sellers set forth in this Agreement will be true and correct in all respects as of the date
of this Agreement and as of the Closing Date (except to the extent such representations and warranties speak as of another date, in which
case such representations and warranties will be true and correct as of such other date), except where the failure of such representations
and warranties to be so true and correct (without giving effect to any limitation as to “materiality” or “Material Adverse
Effect” set forth therein) does not have, and would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect. The Buyer will have received a certificate signed by the Sellers to such effect.

 

(b)
Each of the Sellers and the Company will have performed all of the covenants required to be performed by it under this Agreement at or
prior to the Closing, except where the failure to perform does not have, and would not reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect or materially adversely affect the ability of each of the Sellers and the Company to consummate
the Acquisition or perform its other obligations hereunder. The Buyer will have received a certificate signed by the Sellers to such effect.

 

(c)
The Buyer shall have completed its business, accounting and legal due diligence review of the Company and the Business, its assets and
liabilities and the results thereof shall be reasonably satisfactory to the Buyer.

 

(d)
There shall not have been any occurrence, event, incident, action, failure to act, or transaction since the date of the Financial Statements
that has had or is reasonably likely to cause a Material Adverse Effect.

 

(e)
All applicable waiting periods (and any extensions thereof) will have expired or otherwise been terminated, and the parties hereto will
have received all other authorizations, consents and approvals of all Governmental Entities in connection with the execution, delivery
and performance of this Agreement and the transactions contemplated hereby.

 

(f)   
No temporary, preliminary or permanent restraining Order preventing the consummation of the Acquisition will be in effect.

 

    24

     

    

 

(g)
Each party, as appropriate, shall have obtained any required permits, licenses, approvals or notifications of any Governmental Entities,
or other third parties for which the Sellers will assume responsibility for properly completing any and all necessary forms required when
applying for and securing any necessary transfers.

 

(h)
The Sellers shall have obtained releases of any liens, charges or encumbrances against any of the assets of the Company, at the Sellers’
expense.

 

(i)
The Company shall have delivered evidence reasonably satisfactory to the Buyer of the Company’s corporate organization and proceedings
and its existence in the jurisdiction in which it is incorporated, including evidence of such existence as of the Closing.

 

(j)
The Buyer and each of the Sellers shall have entered into an employment agreement containing a one-year non-competition provision in form
and substance mutually agreed upon by the Buyer and the Sellers.

 

(k)
Justin Francisco and Steven Rubert of the Company shall have entered into change of control agreements containing non-competition provisions
that are in form and substance reasonably satisfactory to the Buyer.

 

(l)
The Buyer shall have obtained on terms and conditions satisfactory to it all of the financing it needs in order to consummate the transactions
contemplated hereby and fund the working capital requirements of the Company after the Closing.

 

(m)   
The Buyer shall have received an opinion of counsel to the Company in form and substance satisfactory to the Buyer.

 

(n)
To the extent that the leased Real Property is owned by the Sellers, the Sellers shall have executed new leases for such Real Property
that are mutually satisfactory to the parties. To the extent that the leased Real Property is not owned by the Sellers, then the Buyer
may require amendments to the existing leases of the Company as a condition to the Closing.

 

(o)
All actions to be taken by the Sellers in connection with consummation of the transactions contemplated hereby and all certificates, opinions,
instruments, and other documents required to effect the transactions contemplated hereby will be satisfactory in form and substance to
the Buyer.

 

7.2
Conditions to Obligation of the Sellers. The obligation of the Sellers to consummate the Acquisition is subject to the satisfaction
or waiver by the Sellers of the following conditions:

 

(a)
The representations and warranties of the Buyer set forth in this Agreement will be true and correct in all respects as of the date of
this Agreement and as of the Closing Date (except to the extent such representations and warranties speak as of another date, in which
case such representations and warranties will be true and correct as of such other date), except where the failure of such representations
and warranties to be so true and correct does not adversely affect the ability of the Buyer to consummate the Acquisition and the other
transactions contemplated by this Agreement. The Sellers will have received a certificate signed on behalf of the Buyer by a duly authorized
officer of the Buyer to such effect.

 

    25

     

    

 

(b)
The Buyer will have performed in all material respects all of the covenants required to be performed by it under this Agreement at or
prior to the Closing except such failures to perform as do not materially adversely affect the ability of the Buyer to consummate the
Acquisition and the other transactions contemplated by this Agreement. The Sellers will have received a certificate signed on behalf of
the Buyer by a duly authorized officer of the Buyer to such effect.

 

(c)
All applicable waiting periods (and any extensions thereof) will have expired or otherwise been terminated and the parties hereto will
have received all other required authorizations, consents and approvals of all Governmental Entities in connection with the execution,
delivery and performance of this Agreement and the transactions contemplated hereby.

 

(d)
No temporary, preliminary or permanent restraining Order preventing the consummation of the Acquisition will be in effect.

 

(e)
Each party, as appropriate, shall have obtained any required permits, licenses, approvals or notifications of any Governmental Entities,
or other third parties for which the Buyer will assume responsibility for properly completing any and all necessary forms required when
applying for and securing any necessary transfers.

 

(f)   
The Buyer and each of the Sellers shall have entered into an employment agreement containing a one-year non-competition provision in form
and substance mutually agreed upon by the Buyer and the Sellers.

 

(g)
All actions to be taken by the Buyer in connection with consummation of the transactions contemplated hereby and all certificates, opinions,
instruments, and other documents required to effect the transactions contemplated hereby will be satisfactory in form and substance to
the Sellers.

 

    26

     

    

 

ARTICLE VIII

TERMINATION; AMENDMENT; WAIVER

 

8.1  Termination
of Agreement. This Agreement may be terminated as follows:

 

(a)
by mutual written consent of the Buyer and the Sellers at any time prior to the Closing;

 

(b)
by either the Buyer or the Sellers if any Governmental Entity will have issued an Order or taken any other action permanently enjoining,
restraining or otherwise prohibiting the transactions contemplated by this Agreement;

 

(c)
by either the Buyer or the Sellers if the Closing does not occur on or before the date that that is ninety (90) days after the later of
the date of delivery to the parties of the Quality of Earnings Report or the date that the Sellers delivers to the Buyer the final Company
Disclosure Schedule in accordance with Section 6.10 hereof; provided that the right to terminate this Agreement under this Section
(c) will not be available to any party whose breach of any provision of this Agreement results in the failure of the Closing to occur
by such time;

 

(d)
by the Buyer if either of the Sellers or the Company has breached their respective representations and warranties or any covenant or other
agreement to be performed by it in a manner such that the Closing conditions set forth in Section 7.1(a) or 7.1(b) would not be satisfied;
or

 

(e)
by the Sellers if the Buyer has breached its representations and warranties or any covenant or other agreement to be performed by it in
a manner such that the Closing conditions set forth in Section 7.2(a) or 7.2(b) would not be satisfied.

 

8.2
Effect of Termination. In the event of termination of this Agreement by either Sellers or the Buyer as provided in Section 8.1,
this Agreement will forthwith become void and have no effect, without any Liability (other than with respect to any suit for breach of
this Agreement) on the part of the Buyer, the Company or the Sellers (or any stockholder, agent, consultant or Representative of any such
party); provided, that the provisions of Sections 10.1, 10.6, 10.7, and this Section 8.2 will survive any termination hereof
pursuant to Section 8.1.

 

8.3
Amendments. This Agreement may not be amended except by an instrument in writing signed on behalf of the Buyer, the Company and
the Sellers.

 

8.4
Waiver. At any time prior to the Closing, the Buyer may (a) extend the time for the performance of any of the covenants, obligations
or other acts of the Sellers and the Company or (b) waive any inaccuracy of any representations or warranties or compliance with
any of the agreements, covenants or conditions of the Sellers or any conditions to its own obligations. Any agreement on the part of the
Buyer to any such extension or waiver will be valid only if such waiver is set forth in an instrument in writing signed on its behalf
by its duly authorized officer. At any time prior to the Closing, the Sellers and the Company, may (a) extend the time for the performance
of any of the covenants, obligations or other acts of the Buyer or (b) waive any inaccuracy of any representations or warranties
or compliance with any of the agreements, covenants or conditions of the Buyer or any conditions to their own obligations. Any agreement
on the part of the Sellers and the Company to any such extension or waiver will be valid only if such waiver is set forth in an instrument
in writing signed by the Sellers and the Company. The failure of any party to this Agreement to assert any of its rights under this Agreement
or otherwise will not constitute a waiver of such rights. The waiver of any such right with respect to particular facts and other circumstances
will not be deemed a waiver with respect to any other facts and circumstances, and each such right will be deemed an ongoing right that
may be asserted at any time and from time to time.

 

    27

     

    

 

ARTICLE IX

INDEMNIFICATION

 

9.1
Survival. The representations and warranties made herein and in any certificate delivered in connection herewith shall survive
for a period of eighteen (18 ) months following the Closing Date, at which time they shall expire; provided, however, that the representations
and warranties set forth in Sections  3.1 (Authority and Enforceability), 3.3 (The Securities), 3.4 (Brokers Fees), 4.1 (Organization,
Qualification and Corporate Power; Authority and Enforceability), 4.3 (Capitalization), 4.6 (Taxes), 4.19 (Brokers Fees), 5.1 (Organization);
5.2 Authorization) and 5.4 (Broker Fees) of this Agreement (the “Fundamental Representations”) shall survive until
the expiration of the applicable statute of limitations. If written notice of a claim has been given prior to the expiration of the applicable
representations and warranties, then notwithstanding any statement herein to the contrary, the relevant representations and warranties
shall survive as to such claim, until such claim is finally resolved. Unless a specified period is set forth in this Agreement (in which
event such specified period will control), all agreements and covenants contained in this Agreement will survive the Closing and remain
in effect indefinitely.

 

9.2
Indemnification by Sellers. From and after the Closing, the Sellers agree to indemnify, defend and save Buyer and its Affiliates,
stockholders, officers, directors, employees, agents and representatives (each, a “Buyer Indemnified Party” and collectively,
the “Buyer Indemnified Parties”) harmless from any and all losses, liabilities, damages, fines, and out-of-pocket costs
and expenses (including reasonable attorneys’ fees) against or affecting such Person; provided, that “Losses”
shall not include punitive damages, speculative damages or damages that are not the reasonably foreseeable consequence of the breach giving
rise to such Losses except, in each case, to the extent such damages are required to be paid to a third party pursuant to a Third-Party
Claim. (individually and collectively, the “Losses”) suffered, sustained or incurred by any Buyer Indemnified Party
arising out of or otherwise by virtue of: (a) any breach of any of the representations or warranties of the Sellers or the Company contained
in Article III or IV of this Agreement; or (b) the failure of Sellers to perform any of their covenants or obligations contained in this
Agreement.

 

9.3
Indemnification by Buyer. From and after the Closing, the Buyer agrees to indemnify, defend and save the Sellers and to the extent
applicable, the Sellers’ Affiliates, employees, agents and representatives (each, a “Seller Indemnified Party”
and collectively the “Seller Indemnified Parties”) harmless from and against any and all Losses sustained or incurred
by any Seller Indemnified Party arising out of or otherwise by virtue of: (a) any breach of any of the representations and warranties
of Buyer contained in Article V of this Agreement or (b) the failure of Buyer to perform any of its covenants or obligations contained
in this Agreement.

 

    28

     

    

 

9.4
Indemnification Procedure.

 

(a)
If a Buyer Indemnified Party or a Seller Indemnified Party seeks indemnification under this Article IX, such party (the “Indemnified
Party”) shall give written notice to the other party (the “Indemnifying Party”) of the facts and circumstances
giving rise to the claim. In that regard, if any Action, Liability or obligation shall be brought or asserted by any third party which,
if adversely determined, would entitle the Indemnified Party to indemnity pursuant to this Article IX (a “Third-Party Claim”),
the Indemnified Party shall promptly notify the Indemnifying Party of such Third-Party Claim in writing, specifying the basis of such
claim and the facts pertaining thereto, and the Indemnifying Party, if the Indemnifying Party so elects, shall assume and control the
defense thereof (and shall consult with the Indemnified Party with respect thereto), including the employment of counsel reasonably satisfactory
to the Indemnified Party and the payment of all necessary expenses. If the Indemnifying Party elects to assume control of the defense
of a Third-Party Claim, the Indemnified Party shall have the right to employ counsel separate from counsel employed by the Indemnifying
Party in any such action and to participate in the defense thereof, but the fees and expenses of such counsel employed by the Indemnified
Party shall be at the expense of the Indemnified Party unless the Indemnifying Party has failed to assume the defense and employ
counsel; in which case the fees and expenses of the Indemnified Party’s counsel shall be paid by the Indemnifying Party. All claims
other than Third-Party Claims (a “Direct Claim”) may be asserted by the Indemnified Party giving notice to the Indemnifying
Party. Absent an emergency or other extenuating circumstance, the Indemnified Party shall give written notice to the Indemnifying Party
of such Direct Claim prior to taking any material actions to remedy such Direct Claim.

 

(b)
In no event shall the Indemnified Party pay or enter into any settlement of any claim or consent to any judgment with respect to any Third-Party
Claim without the prior written consent of the Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed).

 

9.5
Failure to Give Timely Notice. A failure by an Indemnified Party to provide notice as provided in Section 9.4 will not affect
the rights or obligations of any Person except and only to the extent that, as a result of such failure, any Person entitled to receive
such notice was damaged as a result of such failure to give timely notice. Nothing contained in this Section 9.4 shall be deemed to extend
the period for which Sellers’ representations and warranties will survive Closing as set forth in Section 9.1 above.

 

9.6 Limited on
Indemnification Obligation. Notwithstanding anything in this Agreement to the contrary, the liability of the Sellers to the
Buyer Indemnified Parties with respect to claims for indemnification pursuant to Section 9.2(a) (but not with respect to the
Fundamental Representations for which recovery shall not be so limited) is subject to the following limitations:

 

(a)
The Sellers shall not, in the aggregate, be liable to the Buyer Indemnified Parties for Losses arising under Section 9.2(a) (other than
with respect to Fundamental Representations for which recovery shall be limited to the amount of the Purchase Price actually received
by the Sellers in cash or from the receipt of payments under the Buyer Notes) to the extent that the amounts otherwise indemnifiable for
such breaches exceeds an aggregate maximum equal twenty –five percent (25%) of the Purchase Price actually received by the Sellers
in cash or from the receipt of payments under the Buyer Notes.

 

(b)
The Sellers shall not be liable to the Buyer Indemnified Parties for Losses arising under Section 9.2(a) (other than with respect to Fundamental
Representations) until and unless the aggregate amounts indemnifiable for such breaches exceeds $200,000. (the “Deductible”).
In the event the Buyer Indemnified Parties’ claim for Losses, in the aggregate, exceed the Deductible, the Buyer Indemnified Parties
shall only be entitled to recover those Losses in excess of the Deductible.

 

(c)
Neither Party shall be liable to the other Party for Losses arising under Section 9.2 or 9.3, as applicable, unless the claim therefor
is asserted in writing on or prior to the expiration of the applicable representations and warranties.

 

    29

     

    

 

9.7
Payments. Payments of all amounts owing by an Indemnifying Party under this Article IX shall be made promptly upon the determination
in accordance with this Article IX that an indemnification obligation is owing by the Indemnifying Party to the Indemnified Party.

 

9.8
Recoupment under Buyer Notes.

 

(a)
If the Sellers are obligated to indemnify the Buyer or any other Buyer Indemnified Party for any indemnification claim in accordance with
this Article IX, Buyer shall have the right to set-off the amount of such claim against its obligations against the Buyer Notes.

 

(b)
If the Buyer intends to set-off any amount hereunder, the Buyer shall provide not less than thirty (30) days’ prior written notice
to the Sellers of its intention to do so, together with a reasonably detailed explanation of the basis therefor (a “Set-Off Notice”).
If, within twenty (20) days of its receipt of a Set-Off Notice, the Sellers provide the Buyer with written notice of Sellers’ dispute
with Buyer’s right to make such set-off, Buyer and Sellers (and their respective representatives and advisors) shall meet (which
may be accomplished telephonically) in good faith within ten (10) days to attempt to resolve their dispute. If such dispute remains unresolved
despite Buyer’s good faith attempt to meet with the Sellers and resolve such dispute, Buyer may set-off under this Section 9.8 only
(a) with respect to those indemnification claims that have been Finally Determined (as defined below), (b) as described in the first sentence
of Section 9.8(c) or with the prior written consent of the Sellers.

 

(c)
In the event of a dispute with respect to any indemnification claim against Sellers made in good faith pursuant to this Article IX, and
the liability for and amount of Losses therefore, Buyer may place any payments due to the Sellers under the Buyer Notes in escrow to be
held in its attorney’s escrow account, up to the disputed amount until the matter is resolved.

 

ARTICLE X

MISCELLANEOUS

 

10.1
Press Releases and Public Announcement. Neither the Buyer on the one hand, nor the Sellers or the Company on the other, will issue
any press release or make any public announcement relating to this Agreement, the Acquisition or the other transactions contemplated by
this Agreement without the prior written approval of the other party; provided, however, that the Buyer may make regulatory filings referring
to this Agreement or attaching a copy hereof as may be required by applicable law.

 

10.2
No Third-Party Beneficiaries. This Agreement will not confer any rights or remedies upon any Person other than the parties hereto
and their respective successors and permitted assigns.

 

10.3
Entire Agreement. This Agreement (including the Exhibits and the Schedules hereto) constitutes the entire agreement among the parties
hereto and supersedes any prior understandings, agreements or representations by or among the parties hereto, written or oral, to the
extent they related in any way to the subject matter hereof.

 

10.4
Succession and Assignment. This Agreement will be binding upon and inure to the benefit of the parties named herein and their respective
successors and permitted assigns. No party hereto may assign either this Agreement or any of its rights, interests or obligations hereunder
without the prior written approval, in the case of assignment by the Buyer, by the Sellers, and, in the case of assignment by the Sellers
or the Company, the Buyer.

 

    30

     

    

 

10.5
Construction. The parties have participated jointly in the negotiation and drafting of this Agreement, and, in the event an ambiguity
or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties, and no presumption
or burden of proof will arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.

 

10.6
Notices. All notices, requests and other communications hereunder must be in writing and will be deemed to have been duly given
only if delivered personally against written receipt or by facsimile transmission or mailed (by registered or certified mail, postage
prepaid, return receipt requested) or delivered by reputable overnight courier, fee prepaid, to the parties hereto at the addresses of
the parties as specified below:

 

	 	If to the Buyer:	BONNE SANTÉ GROUP, INC
	 	 		 
	 	 		 
	 	 	Attention: 	 
	 	 	Email: 	 

 

	 	with a copy to:	BEVILACQUA PLLC	 
	 	 	1050 Connecticut Avenue, NW	 
	 	 	Suite 500	 
	 	 	Washington, D.C. 200036	 
	 		Attn: Louis A. Bevilacqua	 
	 		Email: 	 
	 		Fax: 	 

 

	 	If to the Sellers:	Steven J. Rubert	 
	 	 		 
	 		 	 
	 	 	Email: 	 
	 	 	 	 
	 	Justin Francisco	 	 
	 	 	 	 
	 	 		 
	 	 		 
	 	 	Email: 	 

 

	 	with a copy to:	Schultis Law Group PLLC	 
	 	 	130 Pondfield Road	 
	 	 	Suite 8	 
	 	 	Bronxville, NY, 10708	 
	 		Attn: Ashleigh Mothershead	 
	 	 	Email: 	 

 

    31

     

    

 

Any party may change the
address to which notices, requests, demands, claims and other communications hereunder are to be delivered by giving the other parties
notice in the manner set forth herein.

 

10.7
Governing Law; Mediation; Arbitration.

 

(a)
This Agreement shall be governed by and construed under the laws of the State of Florida without regard to the choice of law principles
thereof.

 

(b)
The Parties agree to attempt to resolve any dispute, claim or controversy arising out of or relating to this Agreement by mediation, which
shall be conducted under the then current mediation procedures of JAMS or any other procedure upon which the Parties may agree. The Parties
further agree that their respective good faith participation in mediation is a condition precedent to pursuing any other available legal
or equitable remedy, including litigation, arbitration or other dispute resolution procedures. Either party may commence the mediation
process by providing to the other party written notice, setting forth the subject of the dispute, claim or controversy and the relief
requested. Within ten (10) days after the receipt of the foregoing notice, the other party shall deliver a written response to the initiating
party’s notice. The initial mediation session shall be held within thirty (30) days after the initial notice. The Parties agree to share
equally the costs and expenses of the mediation (which shall not include the expenses incurred by each party for its own legal representation
in connection with the mediation). The Parties further acknowledge and agree that mediation proceedings are settlement negotiations, and
that, to the extent allowed by applicable law, all offers, promises, conduct and statements, whether oral or written, made in the course
of the mediation by any of the parties or their agents shall be confidential and inadmissible in any arbitration or other legal proceeding
involving the parties; provided, however, that evidence which is otherwise admissible or discoverable shall not be rendered inadmissible
or non-discoverable as a result of its use in the mediation. The provisions of this section may be enforced by any court of competent
jurisdiction, and the party seeking enforcement shall be entitled to an award of all costs, fees and expenses, including reasonable attorneys’
fees, to be paid by the party against whom enforcement is ordered.

 

(c)
All disputes, controversies or claims between the Parties hereto arising out of or in connection with this Agreement (including its existence,
validity or termination) that cannot be amicably resolved or resolved through mediation shall be finally resolved and settled by arbitration
administered by the JAMS in accordance with its commercial arbitration rules. The arbitration tribunal shall be composed of one (1) arbitrator.
The arbitration will take place in Miami, Florida, and shall be conducted in the English language. The arbitration award shall be final
and binding on the parties, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.
Each party hereto irrevocably submits to the exclusive jurisdiction of the federal and state courts located in the Miami, Florida for
such purpose and for the purpose of exercising any equitable remedies available to the Parties hereunder, and each party hereby waives
any objection such person may have based on improper venue or inconvenient forum in connection with any such action or proceeding in any
such court.

 

10.8
Headings. The descriptive headings contained in this Agreement are included for convenience of reference only and will not affect
in any way the meaning or interpretation of this Agreement.

 

    32

     

    

 

10.9
Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future Law
(a) such provision will be fully severable, (b) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable
provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will
not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid
or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as
similar in terms of such illegal, invalid or unenforceable provision as may be possible.

 

10.10
Expenses. Except as otherwise provided in this Agreement, whether or not the Acquisition is consummated, all expenses incurred
in connection with this Agreement and the transactions contemplated hereby will be paid by the party incurring such expenses. As used
in this Agreement, “expenses” means the out-of-pocket fees and expenses of the financial advisor, counsel and accountants
incurred in connection with this Agreement and the transactions contemplated hereby.

 

10.11
Incorporation of Exhibits and Schedules. The Exhibits and Schedules identified in this Agreement are incorporated herein by reference
and made a part hereof.

 

10.12
Specific Performance. The parties hereto agree that irreparable damage would occur in the event that any provision of this Agreement
was not performed in accordance with the terms hereof and that the parties will be entitled to specific performance of the terms hereof
in addition to any other remedy at Law or equity.

 

10.13
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including
pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

[Signature page follows]

 

    33

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the date first above written.

 

	 	BUYER:
	 	 	 
	 	BONNE SANTÉ GROUP, INC.
	 	 	 
	 	By:	/s/ Alfonso J. Cervantes
	 	Name:	Alfonso J. Cervantes
	 	Title:	Executive Chairman
	 	 	 
	 	COMPANY:
	 	 	 
	 	NEXUS OFFERS, INC.
	 	 	 
	 	By:	/s/ Justin Francisco
	 	Name:	Justin Francisco
	 	Title:	Owner
	 	 	 
	 	SELLERS:
	 	 	 
	 	JUSTIN FRANCISCO
	 	 	 
	 	/s/ Justin Francisco
	 	 	 
	 	STEVEN RUBERT
	 	 	 
	 	/s/ Steven Rubert

 

 

34

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]